Настройки

Укажите год
-

Небесная энциклопедия

Космические корабли и станции, автоматические КА и методы их проектирования, бортовые комплексы управления, системы и средства жизнеобеспечения, особенности технологии производства ракетно-космических систем

Подробнее
-

Мониторинг СМИ

Мониторинг СМИ и социальных сетей. Сканирование интернета, новостных сайтов, специализированных контентных площадок на базе мессенджеров. Гибкие настройки фильтров и первоначальных источников.

Подробнее

Форма поиска

Поддерживает ввод нескольких поисковых фраз (по одной на строку). При поиске обеспечивает поддержку морфологии русского и английского языка
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Ведите корректный номера.
Укажите год
Укажите год

Применить Всего найдено 6069. Отображено 100.
02-02-2012 дата публикации

Process for the synthesis of cleistanthin

Номер: US20120029179A1
Принадлежит: Godavari Biorefineries Ltd

The present invention relates to a process for preparing compound of formula (I) that is Cleistanthin A. The process comprises the steps of reacting compound of formula (II) with compound of formula (III) in the presence of a first solvent, quarternary ammonium salt and first alkali to form compound of formula (IV). The compound of formula (IV) is further treated with a second solvent and a second alkali to form compound of formula (I). The present invention also relates to the preparation of salt of compound of formula (IV) that is Cleistanthin A acetate.

Подробнее
03-05-2012 дата публикации

Phosphonate nucleosides useful as active ingredients in pharmaceutical compositions for the treatment of viral infections, and intermediates for their production

Номер: US20120108531A1
Принадлежит: KU Leuven Research and Development

Disclosed herein are novel phosphonate nucleosides and thiophosphonate nucleosides comprising a phosphonalkoxy-substituted or phosphonothioalkyl-substituted five-membered, saturated or unsaturated, oxygen-containing or sulfur-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base. The invention further relates to compounds having HIV (Human Immunodeficiency Virus) replication inhibiting properties and to compounds having antiviral activities with respect to other viruses. The invention also relates to methods for preparation of all such compounds and pharmaceutical compositions comprising them. The invention further relates to the use of said compounds as a medicine and in the manufacture of a medicament useful for the treatment of subjects suffering from HIV infection, as well as for treatment of other viral, retroviral or lentiviral infections and to the treatment of animals suffering from FIV, viral, retroviral or lentiviral infections.

Подробнее
10-05-2012 дата публикации

Novel method for the synthesis of a trisaccharide

Номер: US20120116065A1
Принадлежит: Glycom AS

The present invention relates to an improved synthesis of a trisaccharide of the formula, novel intermediates used in the synthesis and the preparation of the intermediates.

Подробнее
05-07-2012 дата публикации

In Vivo Polynucleotide Delivery Conjugates Having Enzyme Sensitive Linkages

Номер: US20120172412A1
Принадлежит: Arrowhead Madison Inc

The present invention is directed compositions for delivery of RNA interference (RNAi) polynucleotides to cells in vivo. The compositions comprise amphipathic membrane active polyamines reversibly modified with enzyme cleavable dipeptide-amidobenzyl-carbonate masking agents. Modification masks membrane activity of the polymer while reversibility provides physiological responsiveness. The reversibly modified polyamines (dynamic polyconjugate or DPC) are further covalently linked to an RNAi polynucleotide or co-administered with a targeted RNAi polynucleotide-targeting molecule conjugate.

Подробнее
11-10-2012 дата публикации

Linkable Lewis X Analogs

Номер: US20120258043A1
Принадлежит: Bracco Suisse SA

Disclosed herein is a class of linkable tetrasaccharide compounds that includes the amino phenyl glycoside of sialyl Lewis X (SLe X ) and related analogs. These compounds have conjugatable nucleophilic groups, making them useful in preparing multimeric SLe X compositions. In particular, the disclosed SLe X compounds can be used to prepare selectin binding ligand conjugates by linking them to a reporter moiety, such as a contrast agent, a radiodiagnostic agent, or a cytotoxic or chemotherapeutic agent. The SLe X compounds and conjugates of the invention exhibit binding to selectin that is similar to native Sialyl Le X , and are, therefore, useful for diagnosing and treating selectin-mediated disorders and related conditions.

Подробнее
13-12-2012 дата публикации

Synthesis of purine nucleosides

Номер: US20120316327A1
Принадлежит: GILEAD PHARMASSET LLC

A process for preparing phosphoramidate prodrugs or cyclic phosphate prodrugs of nucleoside derivatives, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof.

Подробнее
03-01-2013 дата публикации

Amphiphiles for protein solubilization and stabilization

Номер: US20130001465A1

The invention provides amphiphiles for manipulating membrane proteins. The amphiphiles can feature carbohydrate-derived hydrophilic groups and branchpoints in the hydrophilic moiety and/or in a lipophilic moiety. Such amphiphiles are useful as detergents for solubilization and stabilization of membrane proteins, including photosynthetic protein superassemblies obtained from bacterial membranes.

Подробнее
31-01-2013 дата публикации

Method for Preventing Cancer Metastasis

Номер: US20130029925A1

The present invention relates to the use of a specific family of glycerolipid compounds of formula (I) described in the detailed description or the manufacture of a medicament for the prevention or for the treatment of cancer metastasis.

Подробнее
14-02-2013 дата публикации

Beta-mannosylceramide and stimulation of nkt cell anti-tumor immunity

Номер: US20130039886A1

β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided.

Подробнее
28-03-2013 дата публикации

Fluorinated fructose derivatives for pet imaging

Номер: US20130078184A1
Принадлежит: University of Alberta

The present invention is directed to fructose-based radiopharmaceuticals, pharmaceutical compositions comprising same, precursors and methods for preparing same, and methods of using same for diagnostic imaging of cancer cells and non-imaging tracer studies.

Подробнее
13-06-2013 дата публикации

Glycolipids of branched chain alkyl oligosaccharides for liquid crystal and related applications

Номер: US20130150567A1
Принадлежит: Individual

Glycolipids of branched chain alkyl oligosaccharides according to this patent comprise of a primary alcohol branched in the 2-position and an oligosaccharide, covalently bond to the alcohol in either α- or β-linkage (shown in Formula I and Formula II). These compounds show particularly interesting phase behavior not found for the corresponding straight chain counterparts. The properties involve an ambient temperature liquid crystalline appearance and thermotropic liquid crystal phase polymorphism. Upon the latter, the formation of cubic phases is considered most interesting with respect to life science applications, e.g. liposome for drug delivery. Depending on the choice of sugar head group and alkyl tail, various levels of water miscibility may be adjusted to meet applications requirements (complete solubility for emulsifier applications, e.g. cosmetic creams, to limited water swelling only, e.g. for the preparation of artificial membranes). The closed structural relationship to natural lipids also make branched chain alkyl oligosaccharides valuable subjects for biochemical investigations, e.g. membrane studies. The range of possible applications for glycolipids of branched chain alkyl oligosaccharides involve material science liquid crystal applications, e.g. optical switches, as well as surfactants and the life science applications (see above).

Подробнее
11-07-2013 дата публикации

Enhanced immunogenicity of tumor associated antigens by addition of alphagal epitopes

Номер: US20130178613A1
Принадлежит: NewLink Genetics Corp

The invention relates to methods and compositions for causing the selective targeting and killing of tumor cells. The present invention describes prophylactic or therapeutic cancer vaccines based on purified TAA proteins or TAA-derived synthetic peptides altered by chemical, enzymatic or chemo-enzymatic methods to introduce αGal epitopes or αGal glycomimetic epitopes, in order to allow for enhanced opsonization of the antigen by natural anti-αGal antibodies to stimulate TAA capture and presentation, thereby inducing a humoral and cellular immune response to the TAA expressed by a tumor. The animal's immune system thus is stimulated to produce tumor specific cytotoxic cells and antibodies which will attack and kill tumor cells present in the animal.

Подробнее
25-07-2013 дата публикации

DRUG-LIGAND CONJUGATES, SYNTHESIS THEREOF, AND INTERMEDIATES THERETO

Номер: US20130190475A1
Принадлежит: SMARTCELLS, INC.

The present invention relates to methods for synthesizing compounds of formula I or pharmaceutically acceptable salts thereof: I wherein each of X, Alk, Alk, and W are as defined and described herein. 3: The method of claim 2 , wherein each occurrence of X is the same ligand.4: The method of claim 2 , wherein LGis —OSu.5. (canceled)2231-. (canceled) International Application No. PCT/US2010/22268 describes conjugate-based systems, methods for their preparation, and use of these conjugates, e.g., as therapeutics. Alternative synthetic methods for drug-ligand conjugates are desired.As described herein, the present invention provides methods for preparing drug-ligand conjugates capable of controlling the pharmacokinetic (PK) and/or pharmacodynamic (PD) profiles of a drug such as insulin in a manner that is responsive to the systemic concentrations of a saccharide such as glucose. Such conjugates include those of formula I:The present invention also provides synthetic intermediates useful for preparing such conjugates. In certain embodiments, an exemplary useful intermediate in the preparation of a drug-ligand conjugate is a conjugate of formula A:wherein X, Alk, Alk, and LGare as defined and described in embodiments herein.The present invention also provides methods for preparing conjugates that include a detectable label instead of a drug as W.Definitions of specific functional groups, chemical terms, and general terms used throughout the specification are described in more detail below. For purposes of this invention, the chemical elements are identified in accordance with the Periodic Table of the Elements, CAS version, Handbook of Chemistry and Physics, 75Ed., inside cover, and specific functional groups are generally defined as described therein. Additionally, general principles of organic chemistry, as well as specific functional moieties and reactivity, are described in Organic Chemistry, Thomas Sorrell, University Science Books, Sausalito, 1999; Smith and March ...

Подробнее
08-08-2013 дата публикации

GLYCOSIDE DERIVATIVES AND USES THEREOF

Номер: US20130203975A1
Принадлежит: NOVARTIS AG

The present invention provides a compound of formula I; 63. The compound of anyone of - claims 1 , or a pharmaceutically acceptable salt thereof claims 1 , wherein n is 0.736. The compound of anyone of - and claims 1 , or a pharmaceutically acceptable salt thereof claims 1 , wherein q is 0.8. The compound of anyone of the preceeding claims claims 1 , or a pharmaceutically acceptable salt thereof claims 1 , wherein V is —OR.9. The compound of anyone of the preceeding claims claims 1 , or a pharmaceutically acceptable salt thereof claims 1 , wherein R claims 1 , R claims 1 , and Rare hydrogen.10. The compound of anyone of the preceding claims claims 1 , or a pharmaceutically acceptable salt thereof claims 1 , wherein Ris halo claims 1 , Calkyl claims 1 , or Ccycloalkyl.11. The compound of anyone of the preceeding claims claims 1 , or a pharmaceutically acceptable salt thereof claims 1 , wherein Ris bromo claims 1 , ethyl or cyclopropyl.12. The compound of anyone of the preceeding claims claims 1 , or a pharmaceutically acceptable salt thereof claims 1 , wherein Ris ethyl.13. The compound of anyone of the proceeding claims claims 1 , or a pharmaceutically acceptable salt thereof claims 1 , wherein X is O.1412. The compound of anyone of - claims 1 , or a pharmaceutically acceptable salt thereof claims 1 , wherein X is S.1512. The compound of anyone of - claims 1 , or a pharmaceutically acceptable salt thereof claims 1 , wherein X is S(O).1612. The compound of anyone of - claims 1 , or a pharmaceutically acceptable salt thereof claims 1 , wherein X is NR.17. The compound of anyone of the proceeding claims claims 1 , or a pharmaceutically acceptable salt thereof claims 1 , wherein Ris Calkyl claims 1 , haloCalkyl claims 1 , Ccycloalkyl claims 1 , phenyl claims 1 , or a 5- to 6-membered heteroaryl.18. The compound of anyone of the proceeding claims claims 1 , or a pharmaceutically acceptable salt thereof claims 1 , wherein Ris methyl.19. The compound of claim 16 , or a ...

Подробнее
22-08-2013 дата публикации

GLYCEROGLYCOLIPID ANTIGEN OF MYCOPLASMA PNEUMONIAE

Номер: US20130217031A1
Принадлежит: M BIO TECHNOLOGY INC.

The present invention provides a novel glyceroglycolipid produced by . The glyceroglycolipid can be used as a diagnostic marker for a disease caused by 2. The compound according to claim 1 , wherein Ris —(CH)CH claim 1 , wherein is 12 claim 1 , 14 claim 1 , 16 or 18.3. The compound according to claim 1 , wherein said compound is selected from the group consisting of:3-O-[(β-D-galactopyranosyl)-(1,6)-(β-D-galactopyranosyl)]-1,2-di-O-acyl-sn-glycerol;3-O-[(β-D-glucopyranosyl)-(1,6)-(β-D-galactopyranosyl)]-1,2-di-O-acyl-sn-glycerol;and salts thereof.4. A composition comprising the compound according to and a carrier thereof.5Mycoplasma pneumoniae. A diagnostic agent for detection of a disease caused by claim 1 , which comprises the compound according to and a carrier thereof.6mycoplasma. The diagnostic agent according to claim 5 , wherein said disease is selected from the group consisting of: pneumonia claim 5 , asthma and a nervous disease.7Mycoplasma pneumoniae. A diagnostic kit for detection of a disease caused by claim 1 , which comprises the compound according to and a carrier thereof.8mycoplasma. The diagnostic kit according to claim 7 , wherein said disease is selected from the group consisting of: pneumonia claim 7 , asthma and a nervous disease.9Mycoplasma pneumoniae. A method for diagnosing a disease caused by claim 7 , comprising the steps of:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'i. bringing the compound according to into contact with a sample from a subject; and'}{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'ii. immunologically detecting or measuring an antibody to the compound according to in the sample.'}10mycoplasma. The diagnostic method according to claim 9 , wherein said disease is selected from the group consisting of: pneumonia claim 9 , asthma and a nervous disease.11. The diagnostic agent according to claim 5 , wherein the compound has galactose at the nonreducing terminus.12. The diagnostic agent according to claim 5 , wherein ...

Подробнее
29-08-2013 дата публикации

QUANTIFICATION METHOD FOR REMAINING LIVER FUNCTION AND NOVEL LIVER RECEPTOR IMAGING AGENT

Номер: US20130225798A1

A test indicator for quantifying remaining liver function is provided. A novel liver receptor imaging agent with liver targeting property is utilized to develop a method for quantifying remaining liver function to serve as test indicator for judging the liver failure outcome in clinic, particularly for judging the necessity of liver transplantation for patients with liver failure or liver disease. The radioactivity uptake of the test indicator was negatively correlated with the extent of liver reserve. The cutoff value of liver reserve for liver transplantation is also disclosed. 1. A liver receptor imaging agent , with a lysine based nitrilo triacetic acid structure as backbone which polymerizes with saccharide groups , to bind with a galactosamine chain or lactose chain , and having a free amino group to be attached to a radioisotope by derivatization.2. The liver receptor imaging agent according to claim 1 , wherein the liver receptor imaging agent is prepared by directly adding the trivalent radioisotope In-111 into DTPA-DCM-Lysine hexa-lactoside claim 1 , and reacting at room temperature with shaking for 15 min.3. The liver receptor imaging agent according to claim 2 , wherein both labeling yield and radiochemical purity of the liver receptor imaging agent are higher than 99% claim 2 , no addition of oxidant and purification are required claim 2 , and the specific radioactivity is 2.5×10Bq/mg.4. The liver receptor imaging agent according to claim 1 , wherein the liver receptor imaging agent polysaccharide chain is selected from the group consisting of In-111-DTPA-AHA-Asp[DCM-Lys(ah-Lac)] claim 1 , In-111-DTPA-DCM-Lys (ahGalNAc) claim 1 , and In-111-DTPA-Lys(GahGalNAc).5. The liver receptor imaging agent according to claim 1 , wherein only 200 nCi/g of the liver receptor imaging agent is required claim 1 , to obtain a clear image.6. The liver receptor imaging agent according to claim 1 , wherein the liver receptor imaging agent is merely accumulated in liver.7. ...

Подробнее
26-09-2013 дата публикации

TANNIN INHIBITORS OF HIV

Номер: US20130252909A1
Принадлежит: UNIVERSITY OF IOWA RESEARCH FOUNDATION

The invention provides a method to prevent or treat HIV-infection with synthetic tannins, and pharmaceutical compositions comprising synthetic tannins. 2. The method of wherein n is 1 claim 1 , m is 1 claim 1 , and p is 1.3. The method of wherein Ris CH.4. The method of wherein Rand Rare G or H.5. The method of wherein Ris G or H.6. The method of wherein Ris H or G and Ris H or G.7. The method of wherein Rand Rare H.8. The method of wherein Ris H.11. The method of wherein n is 0.13. The method of wherein Ror Ris CH.14. The method of wherein Rand/or Rare G.15. The method of wherein n is 1 claim 1 , m is 0 and p is 0.17. The method of wherein Rand/or Rare G.18. The method of wherein Ror Rare CH.20. The method of wherein Ris G.21. The method of wherein Rand Rare H.23. The method of wherein Rand/or Rare G.24. The method of wherein Ris H. This application claims priority of U.S. provisional patent application Ser. No. 61/614,792, filed Mar. 23, 2012, which is incorporated by reference herein.This invention was made with the support of the National Institutes of Health under Grant No. P50 AT004155. The U.S. Government has certain rights in the invention.With more than 33 million people currently infected with human immunodeficiency virus (HIV) and 2 million additional individuals infected each year, there is a worldwide imperative to reduce transmission of this deadly virus. Worldwide, sexual transmission is the primary route of new virus infections. Strategies to reduce spread of this virus can be achieved by reducing virus loads in currently infected individuals (and thereby reducing levels of virus exposure) and/or by blocking sexual transmission by the use of effective and safe microbicides.Clinically useful anti-retrovirals target a number of steps of the HIV-1 life cycle including co-receptor (CCR5) binding, virus membrane/cellular membrane fusion, reverse transcription, integration and proteolytic processing. See, e.g. Martins et al., 15, 1083 (2008). Combination ...

Подробнее
10-10-2013 дата публикации

PROCESS FOR THE PREPARATION OF BENZYLBENZENE SGLT2 INHIBITORS

Номер: US20130267694A1
Принадлежит: Theracos, Inc.

Provided are methods of making compounds having an inhibitory effect on sodium-dependent glucose cotransporter SGLT. The invention also provides synthetic intermediates useful for preparing such compounds. 3. The method of claim 1 , wherein{'sup': '2', 'Ris H;'}{'sup': '3', 'sub': 1', '6', '1', '3', '1', '3', '1', '3', '3', '6', '3', '6', '1', '3, 'Ris selected from the group consisting of C-Calkyl, C-Calkoxy, (C-Calkoxy)C-Calkoxy, C-Ccycloalkyl, and (C-Ccycloalkoxy)C-Calkoxy; and'}{'sup': '4', 'sub': 1', '3, 'Ris selected from the group consisting of H, OH and C-Calkoxy.'}4. The method of claim 1 , wherein Ris selected from the group consisting of C-Calkoxy claim 1 , C-Ccycloalkyl claim 1 , and (C-Ccycloalkoxy)C-Calkoxy.5. The method of claim 1 , wherein Ris selected from the group consisting of ethoxy claim 1 , cyclopropyl and 2-cyclopropoxyethoxy.6. The method of claim 1 , wherein Ris OH.7. The method of claim 1 , wherein{'sup': '2', 'Ris H;'}{'sup': '3', 'Ris selected from the group consisting of ethoxy, cyclopropyl and 2-cyclopropoxyethoxy; and'}{'sup': '4', 'Ris OH.'}8. The method of claim 1 , wherein the ratio of the alkyl-magnesium complex in step (a) to the compound of Formula II is from about 0.95 up to 1.0 (mol/mol).9. The method of claim 1 , wherein the first reaction mixture further comprises an accelerating agent selected from the group consisting of LiCl claim 1 , ZnCl claim 1 , diisobutylaluminum hydride claim 1 , sodium bis(2-methoxyethoxy)aluminum hydride claim 1 , tri-methylsilyl chloride claim 1 , and 2 claim 1 ,2′-oxybis(N claim 1 ,N-dimethylethanamine).10. The method of claim 9 , wherein the first reaction mixture further comprises LiCl.11. The method of claim 9 , wherein the ratio of the accelerating agent to the alkyl-magnesium complex is about 1.0 (mol/mol).12. The method of claim 1 , wherein the first reaction mixture is at a temperature of from about −60 to about −50° C.13. The method of claim 1 , wherein the second reaction mixture ...

Подробнее
21-11-2013 дата публикации

Method for treating obesity

Номер: US20130310330A1
Автор: Anton Leighton
Принадлежит: Rhamnopharma Inc

The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration.

Подробнее
05-12-2013 дата публикации

SYNTHETIC AMPHIPHILES FOR MEMBRANE PROTEIN MANIPULATION

Номер: US20130324707A1
Принадлежит:

The invention provides amphiphilic compounds and methods for manipulating membrane proteins. Compounds of the invention, for example, the compounds of Formulas I-XIX, can be prepared from readily available starting materials. The amphiphilic compounds can manipulate membrane protein at relatively low concentrations compared to many known detergents. The compounds can be used to aid the isolation of membrane proteins, for example, to aid their solubilization and/or purification. The compounds can also be used to aid the functional and structural determination of membrane proteins, including their stabilization and crystallization. 2. A method for solubilizing a membrane protein comprising contacting a membrane protein in an aqueous environment with an effective amount of a compound of claim 1 , and optionally heating the protein and the compound claim 1 , to provide the solubilized protein encapsulated in micelles formed from the compound. This application is a continuation of U.S. patent application Ser. No. 12/731,000, filed Mar. 24, 2010, allowed, and claims priority under 35 U.S.C. §119(e) to U.S. Provisional Patent Application No. 61/162,963, filed Mar. 24, 2009, which applications are incorporated herein by reference.This invention was made with government support under GM075913 and NS028471 awarded by the National Institutes of Health. The government has certain rights in the invention.Isolation and physical characterization of membrane proteins remains a central challenge in biomolecular science. Isolating membrane proteins and obtaining their crystal structures is important to furthering an understanding of their function and role in metabolic pathways. The lack of sufficient methods for membrane protein isolation, purification, and crystallization represents a significant hindrance to fundamental and applied biological research because these proteins perform so many crucial functions in vivo. Membrane proteins are difficult to manipulate and ultimately ...

Подробнее
05-12-2013 дата публикации

PROCESS FOR THE CONVERSION OF A CARBOHYDRATE-CONTAINING FEEDSTOCK

Номер: US20130324708A1
Принадлежит: FURANIX TECHNOLOGIES B.V.

A carbohydrate-containing feedstock is converted in a process by contacting the feedstock in a first step with an alcohol in the presence of a first acid catalyst at a temperature below 100° C. to yield an intermediate product, and contacting at least part of the intermediate product in a second step with an alcohol in the presence of a second acid catalyst at a temperature of at least 100° C. Products of such conversion may include hydroxymethylfurfural, hydroxymethylfurfural ethers, levulinic acid, esters thereof and furfural. 1. A process for the dehydration of a carbohydrate-containing feedstock , which process comprises:contacting the feedstock in a first step with an alcohol in the presence of a first acid catalyst at a temperature below 100° C. to yield an intermediate product; and contacting at least part of the intermediate product in a second step with an alcohol in the presence of a second acid catalyst at a temperature of at least 100° C.2. The process according to claim 1 , wherein the first step is carried out at a temperature of at least 10° C. claim 1 , preferably at a temperature ranging from 30 to 80° C.3. The process according to claim 1 , wherein the contact time of the carbohydrate-containing feedstock and the alcohol with the first acid catalyst in the first step ranges from 0.1 to 12 hr.4. The process according to claim 1 , wherein the carbohydrate is selected from the group consisting of monosaccharides claim 1 , disaccharides claim 1 , oligosaccharides and polysaccharides.5. The process according to claim 4 , wherein the disaccharide is sucrose.6. The process according to claim 4 , wherein the monosaccharide is fructose claim 4 , glucose or a mixture thereof.7. The process according to claim 1 , wherein the carbohydrate-containing feedstock comprises from 50 to 100% wt of carbohydrate claim 1 , based on the weight of the carbohydrate-containing feedstock.8. The process according to claim 1 , wherein in addition to the water that is formed in ...

Подробнее
12-12-2013 дата публикации

Modified sophorolipids as oil solubilizing agents

Номер: US20130331466A1
Принадлежит: Polytechnic Institute of NYU

A method for the development of a library of modified sophorolipids using a wide-range of chemical and enzyme catalyst tools to identify modified sophorolipids that can be used in pure form, as mixtures with other modified sophorolipids, as mixtures with natural sophorolipids, as mixtures with modified and natural sophorolipids, and as mixtures with other compounds known by one skilled in the art for use in the dispersion, solubilization or emulsification of various oil types and nutraceuticals, and modified sophorolipids for use in dispersion, solubilization or emulsification processes.

Подробнее
23-01-2014 дата публикации

SOPHOROLIPID ANALOG COMPOSITIONS

Номер: US20140024816A1
Принадлежит:

A composition of matter comprising sophorolipids as antimicrobial agents, antifungal agents, biopesticides, for uses as drugs to treat HIV, septic shock, cancer, asthma, dermatological conditions, as spermicidal agents, as anti-inflammatory drugs, as ingredients in cosmetics and building blocks for monomers and polymers and self-assembled templates for further chemical elaboration. 2. The sophorolipids and sophorolipid analogs as claimed in claim 1 , wherein Ris a hydrogen and the Ralkyl chain has 15 carbons.3. A composition of matter comprising the sophorolipids and sophorolipid analogs of claim 1 , wherein the sophorolipids and sophorolipid analogs are used as antimicrobial agents claim 1 , as antifungal agents claim 1 , as biopesticides claim 1 , as drugs to treat HIV claim 1 , as drugs septic shock claim 1 , as drugs cancer claim 1 , as drugs asthma claim 1 , as drugs dermatological conditions claim 1 , as spermicidal agents claim 1 , as anti-inflammatory drugs claim 1 , as ingredients in cosmetics claim 1 , and as building blocks for monomers and polymers and self-assembled templates for further chemical elaboration. This patent application is a continuation of and claims the benefit of U.S. patent application Ser. No. 13/080,609 having a filing date of 5 Apr. 2011.1. Technical FieldThe present invention relates generally to the field of sophorolipids and more specifically to new compositions of matter for uses of sophorolipids as antimicrobial and antifungal agents; as biopesticides; for uses as drugs to treat HIV, septic shock, cancer, asthma, and dermatological conditions; as spermicidal agents; as anti-inflammatory drugs; as ingredients in cosmetics; as building blocks for monomers and polymers; and as self-assembled templates for further chemical elaboration.2. Prior ArtSurfactants as cosmetics (neutral, anionic emulsifiers & surfactants); surfactants as antimicrobial and antifungal agents; surfactants as therapeutic agents.Nature has evolved a class of ...

Подробнее
06-02-2014 дата публикации

6"-amino-6"-deoxygalactosylceramides

Номер: US20140037693A1

This invention relates to galactosylceramide compounds.

Подробнее
20-02-2014 дата публикации

Synthetic lta mimetics and use thereof as vaccine component for therapy and/or prophylaxis against gram-positive infections

Номер: US20140050741A1

The present invention relates to synthetic lipoteicoic acid (LTA) mimetics which are useful as vaccine components for therapy and/or prophylaxis of bacterial infection.

Подробнее
27-02-2014 дата публикации

Catalytic hydrogenolysis of a composition of a mixture of oligosaccharide precursors and uses thereof

Номер: US20140057868A1
Принадлежит: Glycom AS

A method for the manufacture of a mixture of human milk oligosaccharides is disclosed. The method involves the catalytic hydrogenolysis of compounds of the general formula 1 and 2. The use of compounds of general formula 1 and 2 in the manufacture of human milk oligosaccharides is also disclosed.

Подробнее
06-03-2014 дата публикации

SACCHARIDE CONJUGATES

Номер: US20140066390A1
Принадлежит: Curators of the University of Missouri

The invention provides a series of novel Lipid A anlogues that are structually simple, synthetically accessible, and capable of blocking the cellular receptor within the signal transduction pathway. The novel Lipid A anlogues can include a monosaccharide core with hydrophobic side chains and amino acid ionic motif. The invention further provides methods of using the compounds and compositions thereof in various therapeutic methods. 2. The compound of wherein X is oxygen and Ris oxygen-linked serine claim 1 , threonine claim 1 , or tyrosine.3. The compound of wherein X is sulfur and Ris sulfur-linked cysteine.4. The compound of wherein the amino group of the serine claim 2 , threonine claim 2 , or tyrosine is protected with a nitrogen protecting group.5. The compound of wherein the nitrogen protecting group is an acyl claim 4 , alkyl claim 4 , or carbamate group.7. The compound of wherein P is an Fmoc group.9. The compound of wherein Rand Rare (C-C)alkyl claim 1 , (C-C)alkenyl claim 1 , or (C-C)alkanoyl groups.10. The compound of wherein Rand Rare tetradecanoyl groups claim 9 , tetradecanyl groups claim 9 , or a combination thereof.12. A composition comprising a compound of and a pharmaceutical carrier claim 1 , diluent claim 1 , or excipient.13. The composition of wherein the composition is formulated for intraperitoneal injection or infusion to a mammal.14. A composition comprising a compound and a pharmaceutical carrier claim 1 , diluent claim 1 , or excipient.15. The composition of wherein the composition is formulated for intraperitoneal injection or infusion to a mammal.16. A method for treating or inhibiting the deleterious effects of endotoxemia comprising administering to a subject afflicted with endotoxemia an effective amount of a composition of wherein the deleterious effects of endotoxemia are thereby treated or inhibited.17. The method of wherein the deleterious effects of endotoxemia are one or more of a reduction in white blood cells claim 16 , a high ...

Подробнее
06-01-2022 дата публикации

SWEETENER AND METHOD OF PRODUCTION THEREOF

Номер: US20220002331A1
Принадлежит: EVONIK OPERATIONS GMBH

A sweetener and to a method of production thereof is provided. The task of the present invention consists of providing a sucrose-based sweetener, in the production of which the step of separation of the residual sucrose from the isomerization stage is not required, and which has excellent properties for further processing, for example it can be formulated as sweets. 1. A sweetener comprising20 wt. % to 75 wt. % of α-D-glucopyranosyl-1,6-D-sorbitol,20 wt. % to 75 wt. % of α-D-glucopyranosyl-1,1-D-mannitol,0.02 wt. % to 15 wt. % of α-D-glucopyranosyl-1,1-D-sorbitol,0.02 wt. % to 15 wt. % of sorbitol and0.02 wt. % to 15 wt. % of mannitol,in each case relative to the total amount of α-D-glucopyranosyl-1,1-D-mannitol, α-D-glucopyranosyl-1,6-D-sorbitol, α-D-glucopyranosyl-1,1-D-sorbitol, sorbitol and mannitolwith the proviso,that the weight ratio of α-D-glucopyranosyl-1,6-D-sorbitol to α-D-glucopyranosyl-1,1-D-mannitol is greater than 1:1.2. A method of production of a sweetener , comprising reacting a carbohydrate mixture containing isomaltulose and sucrose , in the presence of at least one catalyst , which is based on ruthenium (Ru) and/or at least one oxide of ruthenium.3. The method according to claim 2 , wherein the carbohydrate mixture contains 0.01 wt. % to 15 wt. % of sucrose relative to the dry weight of the total carbohydrate mixture.4. The method according to claim 2 , wherein the carbohydrate mixture contains 0.02 wt. % to 30 wt. % of trehalulose relative to the dry weight of the total carbohydrate mixture.5. The method according to claim 2 , wherein the carbohydrate mixture contains 20 wt. % to 70 wt. % of water relative to the total carbohydrate mixture.6. The method according to claim 2 , wherein in the catalyst claim 2 , the ruthenium (Ru) and/or the ruthenium-containing compound is immobilized on a support.7. The method according to claim 6 , wherein the total pore volume of the support according to DIN 66133 is in a range from 0.01 to 3 ml/g.8. The ...

Подробнее
04-01-2018 дата публикации

OLIGOSACCHARIDE-PROTEIN CONJUGATES

Номер: US20180002365A1
Принадлежит:

Provided herein are conjugates comprising a protein and an oligosaccharide of one of Formulae I-VI. Also provided herein are pharmaceutical compositions comprising such conjugates. Further provided herein are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-glycoprotein conjugate. 2: The oligosaccharide-protein conjugate of claim 1 , wherein the oligosaccharide has two mannose-6-phosphate residues.3: The oligosaccharide-protein conjugate of claim 1 , wherein the oligosaccharide has three mannose-6-phosphate residues.4: The oligosaccharide-protein conjugate of claim 1 , wherein the oligosaccharide is Oligosaccharide 82.5: The oligosaccharide-protein conjugate of claim 1 , wherein the oligosaccharide is Oligosaccharide 128 claim 1 , Oligosaccharide 129 claim 1 , or a mixture thereof.6: The oligosaccharide-protein conjugate of claim 1 , wherein the oligosaccharide is Oligosaccharide 130 claim 1 , Oligosaccharide 131 claim 1 , or a mixture thereof.7: The oligosaccharide-protein conjugate of claim 1 , wherein the oligosaccharide is Oligosaccharide 132 claim 1 , Oligosaccharide 133 claim 1 , or a mixture thereof.8: The oligosaccharide-protein conjugate of claim 1 , wherein the oligosaccharide is Oligosaccharide 136.9: The oligosaccharide-protein conjugate of claim 1 , wherein the protein is a glycoprotein.10: The oligosaccharide-protein conjugate of claim 9 , wherein the glycoprotein is a lysosomal enzyme.11: The oligosaccharide-protein conjugate of claim 10 , wherein the lysosomal enzyme is acid α-glucosidase claim 10 , α-galactosidase A claim 10 , acid sphingomyelinase claim 10 , α-L-iduronidase claim 10 , iduronate-2-sulfatase claim 10 , or N-acetylgalactosamine-4-sulfatase.12: The oligosaccharide-protein conjugate of claim 10 , wherein the lysosomal enzyme is acid α-glucosidase.13: A pharmaceutical composition comprising the oligosaccharide-protein conjugate of and an excipient.14. (canceled)15: A method of treating ...

Подробнее
01-01-2015 дата публикации

Sialic Acid Dimers

Номер: US20150005245A1
Принадлежит:

Sialic acid derivatives of the formula (I) 2. The sialic acid derivative according to claim 1 , where the symbols in the formula (I) have the following definitions:{'sup': 1', '2', '1', '3', '2, 'sub': 'm', 'A, Aare identically or differently a group D-[Y-D-]-;'}{'sup': '1', 'Dis identically or differently'}{'sub': 6', '14, 'a) C-C-aryl,'}{'sub': 3', '14', '5', '14, 'b) C-Ccycloalkenyl or C-Ccycloalkadienyl,'}{'sub': 3', '8, 'c) C-Ccycloalkyl,'}d) non-aromatic, saturated or partially unsaturated 5- or 6-membered heterocyclyl, containing one to three nitrogen atoms and/or one oxygen or sulphur atom or one or two oxygen and/or sulphur atoms,e) 5-membered heteroaryl, containing one to four nitrogen atoms or one to three nitrogen atoms and/or one sulphur or oxygen atom,f) 6-membered heteroaryl, containing one to three or one to four nitrogen atoms,g) polycyclic heterocyclic radicals,{'sup': '1', 'the stated groups being unsubstituted or substituted by one or more groups X;'}{'sup': '2', 'Dis identically or differently'}{'sub': 6', '14, 'a) C-Caryldiyl,'}{'sub': 3', '8, 'b) C-Ccycloalkyldiyl,'}c) non-aromatic, saturated or partially unsaturated 5- or 6-membered heterocyclodiyl, containing one to three nitrogen atoms and/or one oxygen or sulphur atom or one or two oxygen and/or sulphur atoms,d) 5-membered heteroaryldiyl, containing one to four nitrogen atoms or one to three nitrogen atoms and one sulphur or oxygen atom,{'sup': '1', 'e) 6-membered heteroaryldiyl, containing one to three or one to four nitrogen atoms, the stated groups being unsubstituted or substituted by one or more groups X;'}{'sup': '1', 'sub': 3', '3', '2', '2', '3, 'Xis identically or differently F, Cl, Br, I, cyano, nitro, hydroxy, mercapto, amino, carboxyl, hydroxylamino, azido, SOM, OSOM, SONH, OPOM, alkyl, haloalkyl, alkenyl, alkynyl, alkyloxy, haloalkyloxy, alkenyloxy, alkynyloxy, alkylthio, alkylamino, dialkylamino, trialkylamino, formyl, alkylcarbonyl, alkylsulphonyl, alkylsulphoxyl, ...

Подробнее
14-01-2016 дата публикации

SYNTHETIC LIPOCHITOOLIGOSACCHARIDE ANALOGS FOR ENHANCING PLANT PERFORMANCE

Номер: US20160007600A1
Принадлежит:

Compounds that are related to natural synthetic lipochitooligosaccharide analogs were chemically synthesized and found to be effective as plant performance enhancers. The compounds are amine-oligosaccharides with a substituent aryl-containing aliphatic carboxylic acid attached at the amine to the terminal amine-sugar unit. The aryl containing aliphatic carboxylic acid terminates with an aromatic ring structure. 2. The compound of having one or more of the followingn is 1 or 2;m is 0 or 1;A is —C(O)—;B is selected from —C≡C— and —CH═CH—, wherein when present the carbon-carbon double bond configuration is selected from cis, trans, and a mixture of cis and trans;{'sub': 3', '2, 'C is an arylene substituted with one or more independently selected from halogen, CN, CF, NO, and C1-6 alkyl;'}{'sub': '3', 'D is selected from H, CH, and linear and branched, saturated and unsaturated, hydrocarbon-based chains containing from 2 to 15 carbon atoms;'}{'sub': '3', 'E is NHC(O)CH;'}{'sup': '1', 'sub': '3', 'Ris selected from H and CH; and'}{'sup': '2', 'sub': '3', 'Ris CHor phenylene.'}3. The compound of whereinn is 1 or 2;m is 0;A is —C(O)—;B is selected from —C≡C— and —CH═CH—, wherein when present the carbon-carbon double bond configuration is selected from cis, trans, and a mixture of cis and trans;{'sub': 3', '2, 'C is an arylene substituted with one or more of independently selected from halogens, CN, CF, NO, and C1-6 alkyl;'}{'sub': '3', 'D is selected from H, CH, and a linear and branched, saturated and unsaturated, hydrocarbon chains containing from 2 to 15 carbon atoms;'}{'sup': '1', 'sub': '3', 'Ris selected from H and CH; and'}{'sup': '2', 'sub': '3', 'Ris CHor phenylene.'}5. The agricultural composition of wherein the compound having the structure (I) whereinn is 1 or 2;m is 0 or 1;A is —C(O)—;B is selected from —C≡C— and —CH═CH—, wherein when present the carbon-carbon double bond configuration is selected from cis, trans, and a mixture of cis and trans;{'sub': 3', '2, ...

Подробнее
14-01-2016 дата публикации

PHOSPHONATE NUCLEOSIDES USEFUL AS ACTIVE INGREDIENTS IN PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF VIRAL INFECTIONS, AND INTERMEDIATES FOR THEIR PRODUCTION

Номер: US20160009750A1
Принадлежит:

The invention is directed to processes of preparing phosphonate nucleosides comprising a phosphonalkoxy-substituted five-membered, saturated or unsaturated, oxygen-containing ring coupled to a heterocyclic nucleobase such as a pyrimidine or purine base. These compounds can be described by general formula (II) 111.-. (canceled)13. The process of claim 12 , wherein the silylating agent is a chlorine-containing silylating agent.14. The process of claim 12 , wherein the silylating agent is tributyldimethylsilyl chloride.15. The process of claim 12 , wherein the reaction is performed in the presence of an organic solvent.16. The process of claim 15 , wherein the organic solvent is acetonitrile.17. The process of claim 12 , wherein the reaction is performed in the presence of a reactant.18. The process of claim 17 , wherein the reactant is imidazole.19. The process of claim 12 , wherein the reaction is performed at a temperature ranging from 0° C. to room temperature.20. The process of claim 12 , wherein the compound is selected from the group consisting of:2-O-tributyldimethylsilyl-L-threonolactone,2-O-tributyldimethylsilyl-3-O-benzoyl-L-threonolactone,2-O-tributyldimethylsilyl-3-O-benzoyl-L-threose,1α,2-di-O-tributyldimethylsilyl-L-threose,1β,2-di-O-tributyldimethylsilyl-L-threose,1α,2-di-O-tributyldimethylsilyl-3-O-(diisopropylphosphonomethyl)-L-threose, and1β,2-di-O-tributyldimethylsilyl-3-O-(diisopropylphosphonomethyl)-L-threose.21. The process of claim 12 , wherein the process further comprises the step of protecting the free hydroxyl group on position 3 of the 2 claim 12 ,3-dihydroxy-dihydro-furan-1-one by acylation.22. The process of claim 21 , wherein said acylation is benzoylation.23. The process of claim 22 , wherein the benzoylation is performed by means of benzoyl chloride in an organic solvent. The present invention relates to a series of novel phosphonate nucleosides and thiophosphonate nucleosides, more specifically phosphonate nucleosides and ...

Подробнее
08-01-2015 дата публикации

GLYCOSYLATED ANTITUMOR ETHER LIPIDS AS NOVEL CANCER STEM CELL CYTOTOXIC AGENTS

Номер: US20150011486A1
Принадлежит:

Glycosylated antitumor ether lipids (GAELs) are effective cytotoxic agents against cancer stem cells. Furthermore, combining GAELs which kill cells by a caspase-independent pathway with agents that kill cells by apoptosis will lead to elimination of the differentiated tumor cells and the undifferentiated cancer stem cells leading to an elimination of the tumor and preventing recurrence. 5. The method according to wherein the cancer is selected from the group consisting of pancreatic cancer claim 4 , ovarian cancer claim 4 , small cell lung cancer and brain cancer.6. The method according to wherein the cancer is a drug-resistant cancer.7. The method according to wherein the cancer is a recurring cancer.8. The method according to wherein the cancer is a metastasized or advanced stage cancer.11. The use according to wherein the cancer is selected from the group consisting of pancreatic cancer claim 9 , ovarian cancer claim 9 , small cell lung cancer and brain cancer.12. The use according to wherein the cancer is a drug-resistant cancer.13. The use according to wherein the cancer is a recurring cancer.14. The use according to wherein the cancer is a metastasized or advanced stage cancer.17. The use according to wherein the cancer is selected from the group consisting of pancreatic cancer claim 15 , ovarian cancer claim 15 , small cell lung cancer and brain cancer.18. The use according to wherein the cancer is a drug-resistant cancer.19. The use according to wherein the cancer is a recurring cancer.20. The use according to wherein the cancer is a metastasized or advanced stage cancer. The instant application claims the benefit of U.S. Provisional Patent Application 61/596,415, filed Feb. 8, 2012.Although there has been progress in diagnosing, treating and managing cancer, there are few treatments for some cancers such as brain, pancreatic and ovarian cancers (1) and even with cancers where treatment results in remission there is often a recurrence of the disease that ...

Подробнее
11-01-2018 дата публикации

ENTEROCOCCUS FAECALIS AND/OR ENTEROCOCCUS FAECIUM ANTIGEN

Номер: US20180009834A1
Принадлежит:

The present invention generally relates to the field of detecting and preventing infectious diseases caused by and/or More specifically, the invention relates to an and/or antigen which comprises at least one unit having the following general formula: 2. The antibody claim 1 , according to claim 1 , wherein the antigen has two sugars that are in the D configuration.3. The antibody claim 1 , according to claim 1 , wherein the antigen comprises a disaccharide consisting of a furanose Gal and a pyranose Glc has a structure that is selected from the following:→-v)-D-Galf-(1→-z)-D-Glcp-(1→-,→-v)-D-Galf-(1→-z)-D-Glcf-(1→-,→-v)-D-Galp-(1→-z)-D-Glcp-(1→- or→-v)-D-Galp-(1→-z)-D-Glcf-(1→-,wherein v and z are in each case 1, 2, 3, 4, 5 or 6.5. The antibody claim 1 , according to claim 1 , wherein claim 1 , for the antigen claim 1 , Ris OH claim 1 , X is O claim 1 , Y is O and CA is lactyl.6. The antibody claim 1 , according to claim 1 , wherein the antigen has a molecular weight of approximately 50 claim 1 ,000 to 150 claim 1 ,000 Da.7. The antibody claim 1 , according to claim 1 , said unit of the antigen occurs at least 100 times.8. The antibody claim 1 , according to claim 1 , that is a recombinant antibody claim 1 , or a recombinant fragment thereof.9. A composition comprising an antibody according to .10. The composition as claimed in claim 9 , comprising a pharmaceutically acceptable carrier.11Enterococcus faecalisEnterococcus faecium.. The composition as claimed in claim 9 , characterized in that it is a vaccine against and/or12Enterococcus faecalisEnterococcus faecium. A kit for detecting and/or in a sample claim 1 , comprising an antibody according to claim 1 , optionally bound to a support.13. The kit according to claim 12 , characterized in that the antigen or the antibody is labeled with a marker.14Enterococcus faecalisEnterococcus faecium,. A method for immunizing a subject against and/or wherein said method comprises administering to the subject an antibody of . ...

Подробнее
08-01-2015 дата публикации

FOAM ADSORPTION

Номер: US20150011741A1
Принадлежит: TECHNISCHE UNIVERSITAET DORTMUND

The present invention provides methods for the isolation of an amphipathic, hydrophobic or hydrophilic compound from a medium that is either hydrophilic or hydrophobic, respectively, said methods comprising allowing the formation and/or accumulation of foam comprising said compound at the medium-gas interface, applying said foam directly onto an adsorbent which effects collapse of said foam, and isolating said adsorbed compound by desorption. 4. The method of claim 1 , wherein said amphipathic compound is a biosurfactant.5. The method of or claim 1 , wherein said amphipathic compound is produced by culturing a host cell capable of producing said biosurfactant.7. The method of any one of the preceding claims claim 1 , wherein said foam formed and/or accumulated at the culture broth-gas interface is non-collapsed.8. The method of any one the preceding claims claim 1 , wherein said adsorbent is adsorbent material in bulk.9. The method of any one the preceding claims claim 1 , wherein said adsorbent is hydrophobic if the solvent of the culture broth is hydrophilic.10. The method of any one the preceding claims claim 1 , wherein said adsorbent is hydrophilic if the solvent of the culture broth is hydrophobic.11. The method of any one of to claim 1 , wherein said cell is a prokaryotic cell.12. The method claim 11 , wherein said cell comprises(i) a rhlA gene or an ortholog thereof; and(ii) a rhlB gene or an ortholog thereof.13. The method of claim 12 , wherein the cell further comprises a rhlC gene or an ortholog thereof.1413. The method of any one of or to claim 12 , wherein said cell is grown at a temperature above 30° C.15. A biosurfactant obtainable by the method of any one of to . The present application claims the benefit of and the priority to an application for “Foam Adsorption” filed on 12 Dec. 2012 with the European Patent Office, and there duly assigned serial number EP 11 192 918. The content of said application filed on 12 Dec. 2012 is incorporated herein by ...

Подробнее
09-01-2020 дата публикации

OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF

Номер: US20200010825A1
Принадлежит:

The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate. 232-. (canceled)34. The method of claim 33 , wherein the protein is a glycoprotein.35. The method of claim 34 , wherein the glycoprotein is a lysosomal enzyme.36. The method of claim 35 , wherein the lysosomal enzyme is acid α-glucosidase claim 35 , α-galactosidase A claim 35 , acid sphingomyelinase claim 35 , or α-L-iduronidase.37. The method of claim 36 , wherein the lysosomal enzyme is acid α-glucosidase.40. An oligosaccharide-protein conjugate produced by the method of .4144-. (canceled)47. The oligosaccharide-protein conjugate of claim 46 , wherein the protein is a glycoprotein.48. The oligosaccharide-protein conjugate of claim 47 , wherein the glycoprotein is a lysosomal enzyme.49. The oligosaccharide-protein conjugate of claim 48 , wherein the lysosomal enzyme is acid α-glucosidase claim 48 , α-galactosidase A claim 48 , acid sphingomyelinase claim 48 , or α-L-iduronidase.50. The oligosaccharide-protein conjugate of claim 49 , wherein the lysosomal enzyme is acid α-glucosidase.51. A pharmaceutical composition comprising the oligosaccharide-glycoprotein conjugate of and an excipient.52. A method of treating a lysosomal storage disorder claim 48 , comprising administering to a mammal an oligosaccharide-glycoprotein conjugate of claim 48 , wherein the protein is a lysosomal enzyme.53. The method of claim 52 , further comprising administering methotrexate to the mammal before claim 52 , after claim 52 , or during treatment with the oligosaccharide-glycoprotein conjugate.5455-. (canceled) This application claims the benefit of U.S. ...

Подробнее
03-02-2022 дата публикации

NEUTRAL GLYCOSYLATED AMIDES AND DIANIONIC GLUCURONIDATED ACIDS AS STABILIZERS FOR BIOLOGICAL MOLECULES

Номер: US20220033427A1
Принадлежит: Extremochem, LDA

The compounds of the present invention are useful for stabilizing biological molecules, particularly in the presence of pH and thermal stress. 4. The compound of claim 2 , wherein X is glucosyl claim 2 , mannosyl or galactosyl claim 2 ,wherein each of Y and Z is H,{'sup': 1', '2', '2', '2', '2', '2', '1', '2, 'sub': 3', '2', '2', '3, 'wherein each of Rand Ris H, or Ris CHand Ris H, or Ris CONHand Ris H or Ris COCHand Ris H, and/or'}{'sup': 3', '4, 'wherein each of Rand Ris H.'}57.-. (canceled)910.-. (canceled)11. The compound of claim 2 ,wherein the hexosyl group is an alpha-anomer; orwherein the hexosyl group is a beta-anomer.12. (canceled)1415.-. (canceled)17. The compound of claim 16 , wherein X is glucuronic acid claim 16 , mannuronic acid or a galacturonic acid claim 16 , and/or wherein each of Y and Z is H.18. (canceled)2021.-. (canceled)22. The compound of claim 16 ,wherein the uronic acid group is an alpha-anomer; orwherein the uronic acid group is a beta-anomer.2328.-. (canceled)29. The compound of claim 16 , wherein the compound is a sodium salt claim 16 , potassium salt claim 16 , calcium salt or magnesium salt.3233.-. (canceled)34. The compound of claim 30 , wherein the uronic acid amide group is an alpha-anomer or a beta-anomer.3538.-. (canceled)39. A composition comprising a biological molecule and at least one compound of claim 1 , wherein the biological molecule is a biopharmaceutical claim 1 , protein claim 1 , nucleotide claim 1 , polypeptide or antibody.40. (canceled)41. The composition of claim 39 , wherein the biological molecule is Insulin; Humulin; Novolin; Insulin human inhalation; Exubera; Insulin aspart; Novolog (aspart); Insulin glulisine; Apidra (glulisine); Insulin lispro; Humalog (lispro); Isophane insulin; NPH; Insulin detemir; Levemir (detemir); Insulin glargine; Lantus (glargine); Insulin zinc extended; Lente; Ultralente; Pramlintide acetate; Symlin; Growth hormone (GH); somatotropin; genotropin; humatrope; norditropin; NorIVitropin; ...

Подробнее
21-01-2016 дата публикации

FLAVOR COMPOSITION CONTAINING HMG GLUCOSIDES

Номер: US20160015063A1
Принадлежит: MARS, INCORPORATED

A flavor composition containing at least one HMG glucoside compound that can be used to enhance the taste of edible compositions including sweet goods, such as confectionery goods, and savory goods, such as pet foods.

Подробнее
19-01-2017 дата публикации

PREPARATION OF MONOSACCHARIDES, DISACCHARIDES, TRISACCHARIDES, AND PENTASACCHARIDES OF HEPARINOIDS

Номер: US20170015695A1
Принадлежит: FORMOSA LABORATORIES, INC.

The present invention provides preparations of monosaccharides, disaccharides, trisaccharides, and pentasaccharides of heparinoids. The present invention also provides novel monosaccharides, disaccharides, trisaccharides and pentasaccharides for use in the preparation of heparinoids. 2. The method of claim 1 , wherein the boron compound is selected from boron trifluoride diethyl etherate or tris(pentafluorophenyl)borane.3. The method of claim 1 , wherein R is phenyl group and R′ is phenyl group.4. The method of claim 1 , wherein the trisaccharide of Formula EDC-1 is in beta position with at least 60% stereoselectivity.6. The method of claim 5 , wherein the inorganic base is selected from potassium carbonate or cesium carbonate.7. The method of claim 5 , wherein R is phenyl group.8. The method of claim 5 , wherein the 2 claim 5 ,2 claim 5 ,2-trichloroacetonitrile is further recycled by distillation.10. The method of claim 9 , wherein the strong acids is selected from HSO claim 9 , CHSOH claim 9 , or CFSOH.11. The method of claim 9 , wherein R is phenyl group and R′ is phenyl group.13. The method of claim 12 , wherein the inorganic base is selected from potassium carbonate or cesium carbonate.14. The method of claim 12 , wherein the 2 claim 12 ,2 claim 12 ,2-trichloroacetonitrile is further recycled by distillation.15. The method of claim 12 , wherein R is phenyl group and R′ is phenyl group.17. The monosaccharide of claim 16 , wherein Ris benzoyl group.19. The monosaccharide of claim 18 , wherein Ris substituted benzyl and Ris benzoyl.21. The monosaccharide of claim 20 , wherein Ris substituted benzyl.23. The trisaccharide of claim 22 , wherein Ris substituted benzyl claim 22 , Ris benzoyl claim 22 , and Ris substituted benzyl. The present application claims priority to U.S. Provisional No. 62/193,548 filed on Jul. 16, 2015, incorporated herein by reference in its entirety.The present invention relates to preparation of monosaccharides, disaccharides, trisaccharides, ...

Подробнее
15-01-2015 дата публикации

The Utility of Nematode Small Molecules

Номер: US20150018291A1
Принадлежит:

The present invention relates to methods of treating immune disorders and/or inflammation using certain modulator compounds. In one embodiment, the present invention provides a method of treating an immune and inflammatory disorders disorder by administering a composition comprising a therapeutically effective dosage of an ascaroside compound, or a mixture of ascaroside compounds, or a mixture containing at least one ascaroside. 2. The method of claim 1 , wherein the disorder is an inflammatory and/or immune disorder.3. The method of claim 1 , wherein Ris H claim 1 , —C(R) claim 1 , —OR claim 1 , —N(R) claim 1 , halogen claim 1 , an alkyl claim 1 , a haloalkyl claim 1 , an alkenyl claim 1 , or a haloalkenyl.4. The method of claim 1 , wherein R is absent claim 1 , H claim 1 , —C(R) claim 1 , —OR claim 1 , —N(R) claim 1 , halogen claim 1 , an alkyl claim 1 , a haloalkyl claim 1 , an alkenyl claim 1 , or a haloalkenyl.6. The method of claim 1 , wherein Ris H claim 1 , —CRRR claim 1 , —C(O)R claim 1 , an alkyl claim 1 , a haloalkyl claim 1 , an alkenyl claim 1 , a haloalkenyl claim 1 , an aryl claim 1 , a heteroaryl claim 1 , a heterocyclyl claim 1 , a cycloalkyl claim 1 , a cycloalkenyl claim 1 , an acyl claim 1 , an amino acid claim 1 , a nucleoside claim 1 , a monosaccharide having 5 or 6 carbon atoms claim 1 , or a bond connecting to Rof another unit of Formula I.7. The method of claim 1 , wherein Ris H claim 1 , —CRRR claim 1 , —C(O)R claim 1 , an alkyl claim 1 , a haloalkyl claim 1 , an alkenyl claim 1 , a haloalkenyl claim 1 , an aryl claim 1 , a heteroaryl claim 1 , a heterocyclyl claim 1 , a cycloalkyl claim 1 , a cycloalkenyl claim 1 , an acyl claim 1 , an amino acid claim 1 , a nucleoside claim 1 , a monosaccharide having 5 or 6 carbon atoms claim 1 , or a bond connecting to Rof another unit of Formula I.8. The method of claim 1 , wherein Ris H claim 1 , —OH claim 1 , —OR claim 1 , —OCRRR claim 1 , —CRRR claim 1 , —NH claim 1 , —NHR claim 1 , —NRR claim 1 , ...

Подробнее
16-01-2020 дата публикации

SYNTHETIC VACCINES AGAINST STREPTOCOCCUS PNEUMONIAE SEROTYPE 2

Номер: US20200016257A1
Принадлежит:

The present invention relates to a synthetic saccharide of general formula (I) that is related to serotype 2 capsular polysaccharide, a conjugate thereof and the use of said saccharide and conjugate for raising a protective immune response in a human and/or animal host. Furthermore, the synthetic saccharide of general formula (I) is useful as marker in immunological assays for detection of antibodies against type 2 bacteria. 2. The saccharide according to claim 1 , wherein x represents 1 claim 1 , or a pharmaceutically acceptable salt thereof.7. The intermediate of general formula (V) according to claim 6 , wherein P claim 6 , Pand Prepresent a benzyl group claim 6 , P claim 6 , Pand Pare independently of each other selected from benzoyl and acetyl group claim 6 , and Prepresents a benzyloxy carbonyl group.8. A conjugate comprising a saccharide of general formula (I) according to covalently linked to an immunogenic carrier through the nitrogen atom of the —O-L-NHgroup.10. A saccharide according to for use in raising a protective immune response in a human and/or animal host.11Streptococcus pneumoniae. A saccharide according to for use in the prevention and/or treatment of a disease caused by type 2.12. A vaccine comprising the saccharide and/or the pharmaceutically acceptable salt thereof according to together with at least one pharmaceutically acceptable adjuvant and/or excipient.13Streptococcus pneumoniaeStreptococcus pneumoniaeStreptococcus pneumoniaeStreptococcus pneumoniaeStreptococcus pneumoniaeStreptococcus pneumoniae. The vaccine composition according to claim 12 , further comprising at least a capsular polysaccharide of and/or a fragment of a capsular polysaccharide of and/or a conjugate of a carrier protein and a capsular polysaccharide of or a fragment of a capsular polysaccharide of claim 12 , wherein is selected from the group comprising type 1 claim 12 , 3 claim 12 , 4 claim 12 , 5 claim 12 , 6A claim 12 , 6B claim 12 , 7F claim 12 , 8 claim 12 , 9N ...

Подробнее
17-01-2019 дата публикации

COMPOSITIONS AND METHODS FOR MODULATING ANGIOPOIETIN-LIKE 3 EXPRESSION

Номер: US20190016748A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Provided herein are methods, compounds, and compositions for reducing expression of an ANGPTL3 mRNA and protein in an animal. Also provided herein are methods, compounds, and compositions for reducing lipids and/or glucose in an animal. Such methods, compounds, and compositions are useful to treat, prevent, delay, or ameliorate any one or more of cardiovascular disease and/or metabolic disease, or a symptom thereof, in an individual in need thereof. 126.-. (canceled)28. The compound of claim 27 , wherein the nucleobase sequence of the modified oligonucleotide is at least 85% claim 27 , at least 90% claim 27 , at least 95% claim 27 , or 100% complementary to SEQ ID NOs: 1.29. The compound of claim 27 , wherein the modified oligonucleotide comprises at least one modified internucleoside linkage.30. The compound of claim 29 , wherein the modified internucleoside linkage is a phosphorothioate internucleoside linkage.31. The compound of claim 27 , wherein the modified oligonucleotide comprises at least one modified sugar.32. The compound of claim 31 , wherein at least one modified sugar is selected from a bicyclic sugar claim 31 , a 2′-O-methoxyethyl modified sugar claim 31 , a constrained ethyl modified sugar claim 31 , a 3′-fluoro-HNA or a 4′-(CH)—O-2′ bridge claim 31 , wherein n is 1 or 2.33. The compound of claim 27 , wherein at least one nucleoside comprises a modified nucleobase.34. The compound of claim 33 , wherein the modified nucleobase is a 5-methylcytosine.35. The compound of claim 27 , wherein the modified oligonucleotide comprises:a gap segment consisting of linked deoxynucleosides;a 5′ wing segment consisting of linked nucleosides;a 3′ wing segment consisting of linked nucleosides;wherein the gap segment is positioned between the 5′ wing segment and the 3′ wing segment and wherein each nucleoside of each wing segment comprises a modified sugar.36. The compound claim 27 , wherein the modified oligonucleotide comprises:a gap segment consisting of ten linked ...

Подробнее
17-01-2019 дата публикации

Compositions, methods and treatments for inhibiting cell adhesion and virus binding and penetration

Номер: US20190017095A1
Автор: Khushi L. Matta
Принадлежит: Tumorend LLC

Disclosed herein are glyco-decoy acceptor compositions that sidetrack or inhibit the activity of biosynthetic enzymes participating in synthesis of ligands binding at selectin, galectin and siglecs receptors; methods of their preparation and uses in drug discovery and in treatments of diseases.

Подробнее
21-01-2021 дата публикации

Glycan Analysis and Profiling

Номер: US20210017213A1
Принадлежит: Seattle Genetics Inc

The invention provides methods and tools, for example, glycan arrays, for the analysis of glycans and anti-glycan antibodies. Embodiments of the invention may be used to detect proteins, antibodies, diseases and/or pathogenic agents. In other embodiments, methods of the invention are used to develop or optimize arrays and antibodies.

Подробнее
21-01-2021 дата публикации

GALNAC PHOSPHORAMIDITES, NUCLEIC ACID CONJUGATES THEREOF AND THEIR USE

Номер: US20210017214A1
Принадлежит:

This invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N-Acetylgalactosamine phosphoramidite molecules and to conjugates of nucleic acid molecules with N-Acetylgalactosamine containing molecules. Also provided are methods for preparation of these molecules and possible uses thereof, in particular in medicine. 117.-. (canceled)19. Use of a compound according to as a medicament. This application is divisional under 35 U.S.C. § 120 of application Ser. No. 15/517,685 filed Apr. 7, 2017 which is a national stage application under 35 U.S.C. § 371 of PCT Application No. PCT/EP2015/073331 filed Oct. 9, 2015 which claims priority to European Patent Application No. EP14188444.5 filed Oct. 10, 2014 and, European Patent Application No. 15181807.7 filed Aug. 20, 2015, of which each of these applications are hereby incorporated by reference in their entirety.This invention generally relates to the field of phosphoramidite derivatives. In particular, the invention relates to N-Acetylgalactosamine phosphoramidite molecules and to conjugates of nucleic acid molecules with N-Acetylgalactosamine containing molecules. Also provided are methods for preparation of these molecules and possible uses thereof, in particular in medicine.In recent years, approaches have been developed to use nucleic acid molecules in therapy. To favorably influence pharmaceutically relevant properties, the nucleic acid molecules have been conjugated to certain ligands such as peptides, lipids, sterols, and carbohydrates. Nucleic acid conjugates have been extensively evaluated for use in siRNAs, where they are considered essential in order to obtain sufficient in vivo potency. For example, by attachment of a conjugate moiety containing terminal galactose or a derivative thereof to the nucleic acid, thereby targeting the nucleic acid molecule to hepatocytes via binding to the asialoglycoprotein receptor (ASGPR), see for example WO2009/073809, WO2011/ ...

Подробнее
28-01-2016 дата публикации

SYNTHETIC LIPOAMINO ACID GLUCOSAMINE DERIVATIVES FOR IMPROVEMENT OF PLANT GROWTH AND YIELD

Номер: US20160021879A1
Принадлежит: E. I. DU PONT DE NEMOURS AND COMPANY

The invention provides compounds, formulations and methods for improving plant emergence, growth and yield. More specifically, the present invention relates to compositions comprising the synthetic lipoamino acid glucosamine compounds of Formula I. These compounds may be applied to plant propagating materials, including seeds and other regenerable plant parts, including cuttings, bulbs, rhizomes and tubers. They may also be applied to foliage, or soil either prior to or following planting of plant propagating materials. Such applications may be made alone or in combination with fungicides, insecticides, nematicides and other agricultural agents used to improve plant growth and crop yield. The compounds of Formula I can improve the agronomic performance of a variety of crops including barley, canola, corn, potato, soybean and wheat. 10. An agricultural composition comprising the compound of claim 1 , wherein the compound is present in the formulation at a concentration of 10M to 10M.11. The agricultural composition of claim 10 , wherein the compound is present in the formulation at a concentration of about 10M.12. An agricultural composition comprising the compound of claim 1 , wherein the composition is applied to propagating material of a plant.13. The composition of claim 12 , wherein the plant is a legume.14. The composition of claim 13 , wherein the legume is soybean.15. The composition of claim 12 , wherein the composition is applied to propagating material of the plant to provide improved growth.16. The composition of claim 12 , wherein the propagating material is seed.17. The composition of claim 15 , wherein the composition is applied to seed to accelerate the rate of germination.18. The composition of claim 12 , further comprising one or more insecticides claim 12 , fungicides claim 12 , nematocides claim 12 , bactericides claim 12 , acaricides claim 12 , entomopathogenic bacteria claim 12 , viruses or fungi claim 12 , growth regulators such as rooting ...

Подробнее
25-01-2018 дата публикации

ENHANCEMENT OF CELL CRYOPRESERVATION WITH GLYCOLIPIDS

Номер: US20180020658A1
Принадлежит: TISSUE TESTING TECHNOLOGIES LLC

Living cellular material may be preserved by incubating the cellular material in a culture medium containing at least one glycolipid, and then subjecting the cellular material to a preservation protocol. 1. A method for preserving living cellular material , comprising:exposure of the cellular material to medium containing at least one glycolipid and a cryoprotectant for a predetermined amount of time; andafter the exposure, subjecting the cellular material to a preservation protocol comprising cryopreservation at a cryopreservation temperature of about −80° C. or less.2Tipula trivittat, Ceruchus piceus, Solanum dulcamara, Dendroides canadensisCucujus clavipes.. The method of claim 1 , wherein the at least one glycolipid is an anti-freeze glycolipid isolated from one or more member selected from the group consisting of claim 1 , and3. The method of claim 1 , wherein the at least one glycolipid comprises a β-mannopyranosyl-(1→4) β-xylopyranose backbone and a lipophilic moiety selected from the group consisting of an alkyl chain substituted with one or more hydroxyl groups; an alkyl chain substituted with one or more carboxy groups; a fatty acid; a mono-glyceride; di-glyceride; tri-glyceride; a sterol claim 1 , and a phospholipid.4. The method of claim 1 , wherein the cellular material is exposed to the medium for 6-72 hours before subjecting the cellular material to the preservation protocol claim 1 , and the preservation protocol comprises cooling the cellular material from 37° C. to a freezing temperature of the medium at a cooling rate in the range of from 10 to 30° C. per minute.5. The method of claim 1 , wherein the preservation protocol comprises cooling the cellular material in the medium claim 1 , where the medium contains at least one glycolipid at a concentration in the range of from 1 pM to 1 nM.6. The method of claim 1 , wherein the medium is a cryoprotectant composition and the cryoprotectant is present in the cryoprotectant composition in an amount of ...

Подробнее
17-04-2014 дата публикации

Mannose derivatives for treating bacterial infections

Номер: US20140107049A1
Принадлежит: Vertex Pharmaceuticals Inc

The present invention relates to compounds useful for the treatment or prevention of bacteria infections. The invention also provides pharmaceutically acceptable compositions containing the compounds and methods of using the compositions in the treatment of bacteria infections. The invention also provides processes for making the compounds of the invention. The compounds of the present invention are represented by the following structure of Formula A: wherein the variables are as described herein.

Подробнее
22-01-2015 дата публикации

NOVEL SUGAR-DERIVED GELATOR

Номер: US20150025157A1
Принадлежит:

There is provided a novel gelator containing a sugar derivative. A gelator including a compound of Formula (1) or Formula (2): 4. A gel comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'the gelator as claimed in ; and'}a hydrophobic organic solvent, a hydrophilic organic solvent, water, a hydrophilic organic solution, a hydrophobic organic solution, or an aqueous solution.5. The gel according to claim 4 , whereinthe hydrophobic organic solvent is at least one selected from the group consisting of plant oils, esters, silicone oils, and hydrocarbons.6. The gel according to claim 4 , whereinthe hydrophilic organic solvent is at least one selected from the group consisting of methanol, ethanol, 2-propanol, i-butanol, pentanol, hexanol, 1-octanol, isooctanol, acetone, cyclohexanone, acetonitrile, dioxane, glycerol, propylene glycol, ethylene glycol, and dimethyl sulfoxide.7. The gel according to claim 4 , whereinthe hydrophilic organic solution is a mixed solvent of the hydrophilic organic solvent selected from the group consisting of methanol, ethanol, 2-propanol, i-butanol, pentanol, hexanol, 1-octanol, isoctanol, acetone, cyclohexanone, acetonitrile, dioxane, glycerol, propylene glycol, ethylene glycol, and dimethyl sulfoxide and water.8. The gel according to claim 4 , whereinthe hydrophobic organic solution is a mixed solvent of the hydrophobic organic solvent selected from the group consisting of plant oils, esters silicone oils, and hydrocarbons and water.9. The gel according to claim 4 , whereinthe aqueous solution is an aqueous solution containing an organic acid, an inorganic acid, at least one inorganic salt selected from the group consisting of inorganic carbonates, inorganic sulfates, inorganic phosphates, and inorganic hydrogen phosphates, or at least one organic salt selected from the group consisting of acetates, lactates, citrates, organic amine hydrochlorides, and organic amine acetates.10. The gel according to claim 9 , whereinthe organic ...

Подробнее
28-01-2021 дата публикации

3-O-SULFO-GALACTOSYLCERAMIDE ANALOGS AS ACTIVATORS OF TYPE II NKT CELLS AND USES THEREOF

Номер: US20210023110A1
Принадлежит:

Disclosed is a compound of the formula (I) or (II): wherein a f are as described herein. The compounds are useful in the activation of Type II NKT cells and in treating cancer. 8. A composition comprising a compound claim 1 , salt claim 1 , solvate claim 1 , stereoisomer claim 1 , or mixture comprising stereoisomers of and a pharmaceutically acceptable carrier.9. The composition of further comprising a therapeutically effective amount of an α-galactosylceramide or a salt or solvate thereof.10. The composition of further comprising granulocyte-macrophage colony-stimulating factor (GM-CSF) and/or one or more cytokines that induce cellular immunity.11. The composition of claim 10 , wherein the one or more cytokines that induce cellular immunity comprises interleukin (IL)-12 and/or IL-15.12. The composition of claim 8 , further comprising at least one T-cell co-stimulatory molecule selected from the group consisting of B7-1 claim 8 , B7-2 claim 8 , B7-3 claim 8 , B7-H claim 8 , Intercellular Adhesion Molecule (ICAM) 1 claim 8 , ICAM2 claim 8 , ICAM3 claim 8 , LFA1 claim 8 , LFA2 claim 8 , LFA3 claim 8 , CD40L claim 8 , OX40L and 4-1BBL.13. The composition of claim 8 , further comprising at least one Toll-like Receptor (TLR) ligand.14. The composition of claim 13 , wherein the at least one TLR ligand is a ligand for a molecule selected from the group consisting of TLR2 claim 13 , TLR3 claim 13 , TLR4 claim 13 , TLR5 claim 13 , TLR7 claim 13 , TLR8 claim 13 , and TLR9.15. The composition of claim 8 , further comprising a vaccine.16. The composition of wherein the vaccine comprises one or more T cell receptor gamma alternate reading frame protein (TARP) peptides selected from the group consisting of 29-37-9V claim 15 , 27-35 claim 15 , 1-20 claim 15 , 11-30 claim 15 , 21-40 claim 15 , 31-50 and 41-58 in combination with Sargramostin (GM-CSF) emulsified in Montanide ISA 51 VG.17. The composition of claim 8 , further comprising an antibody.18. The composition of claim 17 , ...

Подробнее
01-02-2018 дата публикации

SYNTHETIC GLUCOPYRANOSYL LIPID ADJUVANTS

Номер: US20180028649A1
Принадлежит: Infectious Disease Research Institute

Compounds, particularly, glucopyranosyl lipid adjuvant (GLA) compounds, having the following structure (I) are provided: 4. A GLA compound according to claim 3 , wherein x is selected from an integer from 10-12.11. A vaccine composition comprising a compound of any one of - in combination with an antigen or a recombinant expression vector encoding an antigen.12. The vaccine composition of wherein the recombinant expression construct is viral vector.13. The vaccine composition of wherein the viral vector is selected from the group consisting of an adenovirus vector claim 12 , an adeno-associated virus vector claim 12 , a herpesvirus vector claim 12 , a lentivirus vector claim 12 , a poxvirus vector and a retrovirus vector.14. A method of eliciting or enhancing an antigen-specific immune response in a subject claim 11 , the method comprising administering to the subject a vaccine composition of .15. A pharmaceutical composition comprising a compound of any one of - and pharmaceutically acceptable carrier or excipient.16. A method for stimulating a non-specific immune response in a subject comprising administering to the subject a pharmaceutical composition of . This application claims the benefit under 35 U.S.C. §119(e) of U.S. Provisional Patent Application No. 61/184,703 filed Jun. 5, 2009, which is incorporated herein by reference in its entirety.The present invention relates to the field of pharmaceutical and vaccine compositions. More specifically, embodiments described herein relate to pharmaceutical and vaccine compositions, as well as related prophylactic and therapeutic methods, wherein the compositions comprise a glucopyranosyl lipid adjuvant (GLA) as described herein.The immune system of higher organisms has been characterized as distinguishing foreign agents (or “non-self”) agents from familiar or “self” components, such that foreign agents elicit immune responses while “self” components are ignored or tolerated. Immune responses have traditionally been ...

Подробнее
24-04-2014 дата публикации

Modification of trehalose-6-phosphate levels in plants

Номер: US20140113820A1
Принадлежит: Oxford University Innovation Ltd

Compounds which are trehalose-6-phosphate or trehalose-6-phosphonate precursors of formula (I) or agriculturally acceptable salts thereof are provided: (I) The compounds are useful in increasing starch production in plants.

Подробнее
29-01-2015 дата публикации

PROCESS FOR THE PRODUCTION OF FONDAPARINUX SODIUM

Номер: US20150031865A1
Принадлежит: ScinoPharm Taiwan, Ltd.

The present invention provides novel processes for the preparation of Fondaparinux sodium by using the compound of formula ABC5 4. A process of claim 3 , wherein step a) is conducted in the presence of a base and trichloroacetonitrile.5. A process of claim 4 , wherein the base is selected from the group consisting of DBU and potassium carbonate.6. A process of claim 3 , wherein step b) is conducted in an organic solvent in the presence of a promoter.7. A process of claim 6 , wherein the organic solvent is selected from the group consisting of diethyl ether claim 6 , methyl tert-butyl ether claim 6 , isopropyl ether claim 6 , diglyme claim 6 , toluene claim 6 , DCM and mixtures thereof.8. A process of claim 7 , wherein the mixture is 0-20% toluene or 0-20% dichloromethane (DCM) in methyl tert-butyl ether (MTBE) by volume of solvent mixture.9. A process of and claim 7 , wherein the promoter is selected from the group consisting of TESOTf claim 7 , TMSOTf claim 7 , TfOH claim 7 , TBSOTf and mixtures thereof.14. The process of claim 13 , wherein the ratio of toluene/MTBE is about 20%. Not applicableFondaparinux sodium (CAS 114870-03-0) is a member of oligosaccharides/heparins with a chemical name of O-[2-Deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl]-(1-4)-O-(beta-D-glucopyranurosonyl)-(1-4)-O-[2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl]-(1-4)-O-(2-O-sulfo-alpha-L-idopyranurosonyl)-(1-4)-O-[2-deoxy-1-O-methyl-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranoside]decasodium salt, which developed by Choay, S. A. (see U.S. Pat. No. 4,818,816). The compound is a synthetic pentasaccharide Factor Xa inhibitor which is indicated as an anticoagulant drug used for the prevention of deep vein thrombosis in patients who have had orthopedic surgery as well as for the treatment of deep vein thrombosis and pulmonary embolism. It was approved by the United States Food and Drug Administration in 2001, marketed under the trade name Arixtra™ which is administrated ...

Подробнее
29-01-2015 дата публикации

PROCESS FOR THE PRODUCTION OF FONDAPARINUX SODIUM

Номер: US20150031866A1
Принадлежит: ScinoPharm Taiwan, Ltd.

The present invention provides improved processes of preparing Fondaparinux sodium comprising converting a compound of formula ABCDE4 to Fondaparinux sodium at a reaction pH of no more than about 9.0. In some embodiments, the intermediates for the synthesis of Fondaparinux sodium, are also provided. 2. A process of claim 1 , wherein the conversion is conducted at a reaction pH of about 8.0 to 9.0.3. A process of claim 1 , wherein the conversion is conducted in the presence of a sulfur trioxide-amine complex.4. A process of claim 3 , wherein the sulfur trioxide-amine complex is selected from the group consisting of sulfur trioxide-pyridine complex claim 3 , sulfur trioxide-trimethylamine complex claim 3 , sulfur trioxide-triethylamine complex claim 3 , sulfur trioxide-dimethylethylamine complex claim 3 , sulfur trioxide-dimethylaniline complex claim 3 , and mixtures thereof.5. A process of claim 4 , wherein the sulfur trioxide-amine complex is sulfur trioxide-trimethylamine complex.7. A process of claim 1 , wherein the compound of formula ABCDE4 is purified with activated charcoal prior to the conversion.9. A process of claim 8 , wherein the sulfur trioxide-trialkylamine complex is selected from the group consisting of sulfur trioxide-trimethylamine complex claim 8 , sulfur trioxide-triethylamine complex and mixtures thereof.10. A process of claim 9 , wherein the sulfur trioxide-trialkylamine complex is sulfur trioxide-trimethylamine complex.11. A process of claim 8 , wherein the process is conducted at a reaction pH of no more than about 9.0.12. A process of claim 11 , wherein the reaction pH is from about 8.0 to 9.0. Not applicableFondaparinux sodium (CAS 114870-03-0) is a member of oligosaccharides/heparins with a chemical name of O-[2-Deoxy-6-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl]-(1-4)-O-(beta-D-glucopyranurosonyl)-(1-4)-O-[2-deoxy-3,6-di-O-sulfo-2-(sulfoamino)-alpha-D-glucopyranosyl]-(1-4)-O-(2-O-sulfo-alpha-L-idopyranurosonyl)-(1-4)-O-[2-deoxy-1-O- ...

Подробнее
04-02-2016 дата публикации

GLYCOSIDE DERIVATIVES, PREPARATION THEREOF AND USE THEREOF AS PROSTHETIC GROUPS

Номер: US20160031923A1
Принадлежит:

The present invention relates to glycoside-derived compounds, to the processes for preparing same and to the use thereof as prosthetic groups for radiolabelling biomolecules. These compounds are co-azido-alkyl 6-deoxy-6-[F]-fluoroglycosides of formula (I), in which: k is equal to 2 or 3; n is an integer between 1 and 5; R is independently H or a C-Calkyl group, m being an integer between 0 and 2 if k=2 and m between 0 and 3 if k=3; and X is chosen from the group comprising O, S, CHand NR′, in which R′ is independently a C-Calkyl group or an aryl group, including all the stereoisomers thereof. 113-. (canceled)16. A method for synthesising the compound of claim 14 , comprising the steps of:{'sub': 2', '6, 'forming, on a hexopyranose or pentofuranose compound and at anomeric position, a C-Calkyl spacer arm terminating in an azide group;'}inserting a leaving group at 6-position if k=3 or at 5-position if k=2 and protector groups on the other positions;incorporating fluorine at 6-position if k=3 or at 5-position if k=2; anddeprotecting the other positions.17. The method of claim 16 , wherein the insertion of a leaving group at 6-position if k=3 or at 5-position if k=2 and of protector groups at the other positions comprises the inserting of a first protector group at 6-position if k=3 or at 5-position if k=2 and of a second protector group at the other positions claim 16 , the deprotection of the first protector group at 6-position if k=3 or at 5-position if k=2 by a hydroxyl group and the inserting of the leaving group at 6-position if k=3 or at 5-position if k=2.18. The method of claim 17 , wherein the first protector group if a trityl ether and the second protector group is an acetate.19. A method for synthesising the compound of claim 15 , comprising the steps of:{'sub': 2', '6, 'forming, on a hexopyranose or pentofuranose compound and at anomeric position, a C-Calkyl spacer arm terminating in an azide group;'}inserting a leaving group at 6-position if k=3 or at 5- ...

Подробнее
31-01-2019 дата публикации

COMPOUND CONTAINING DEXPANTHENOL

Номер: US20190031699A1
Автор: Seibel Juergen, TIMM MALTE
Принадлежит:

A compound contains a chemical dexpanthenol bound to a saccharide. A corresponding compound for use in therapeutic and/or cosmetic methods is also provided. The compound may be a skincare compound or a compound configured to be used in prophylaxis of skin diseases and/or treatment of skin diseases or a compound configured to be used as a medicament for accelerating wound healing. 1. A compound , comprising a dexpanthenol chemically bonded to a saccharide.2. The compound according to claim 1 , wherein the dexpanthenol and the saccharide are chemically bonded to one another by a glycosidic bond.3. The compound according to claim 1 , wherein the saccharide is a monosaccharide.4. The compound according to claim 3 , wherein the monosaccharide is selected from the group consisting of hexoses and pentoses.5. The compound according to claim 4 , wherein the hexoses are selected from the group consisting of α-glucose claim 4 , β-glucose claim 4 , α-fructose claim 4 , β-fructose claim 4 , α-galactose and β-galactose claim 4 , α-mannose and β-mannose.6. The compound according to claim 4 , wherein the pentoses are selected from the group consisting of arabinose and xylose.7. The compound according to claim 5 , wherein the α-glucose is bonded to the dexpanthenol by a glycosidic bond.9. The compound according to claim 1 , wherein the compound is at least one of a therapeutic or cosmetic compound.10. The compound according to claim 1 , wherein the compound is a skincare compound.11. The compound according to claim 1 , wherein the compound is configured to be used in at least one of prophylaxis of skin diseases or treatment of skin diseases.12. The compound according to claim 1 , wherein the compound is configured to be used as a medicament for accelerating wound healing. This is a continuation application, under 35 U.S.C. § 120, of copending international application No. PCT/EP2017/057038, filed Mar. 24, 2017, which designated the United States; this application also claims the ...

Подробнее
31-01-2019 дата публикации

Modified hexa-acylated neisserial LPS

Номер: US20190031700A1

The present invention relates to neisserial LPS having a hexa-acylated lipid A moiety, wherein the hexa-acylated lipid A moiety is modified as compared to the lipid A moiety of a wild-type neisserial LPS in that it comprises a palmitoleoyl instead of a lauroyl secondary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety. The invention further relates to mixtures of the hexa-acylated LPS with the corresponding penta-acylated LPS, lacking a secondary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety. The invention also relates to neisserial bacteria that have been genetically modified to reduce expression of the endogenous lpxL1 gene and to introduce expression of a heterologous thermosensitive lpxP gene for producing the hexa- and penta-acylated LPS. By selecting the time and/or temperature at which the bacterium is grown, it is feasible to increase or decrease the amount of hexa-acylated lipid A structure relative to the corresponding penta-acylated structure and thereby modulate the TLR4 agonist activity of the neisserial LPS of the invention, to the exact level of activity required for a particular immunotherapeutic approach. 140-. (canceled)41. A composition comprising a neisserial LPS having a hexa-acylated lipid A moiety , wherein the hexa-acylated lipid A moiety is modified as compared to the lipid A moiety of a wild-type neisserial LPS in that it has a palmitoleoyl (instead of a lauroyl) as secondary acyl chain bound to the primary acyl chain on the glucosamine at the non-reducing end of the lipid A moiety.42Neisseria meningitidis, Neisseria gonorrhoeaeNeisseria lactamica.. The composition of claim 41 , wherein claim 41 , except for the hexa-acylated lipid A moiety claim 41 , the LPS has the structure of LPS of or43Neisseria meningitidis, Neisseria gonorrhoeaeNeisseria lactamica. The composition of claim 42 , wherein the or is at least one of lgtB and galE.45. The composition of claim 41 , wherein the ...

Подробнее
09-02-2017 дата публикации

RECTANGULAR PARALLELEPIPEDAL MALTITOL

Номер: US20170037073A1
Принадлежит:

The invention concerns maltitol crystals, characterized in that they have a rectangular parallelepipedal shape and have a length to width dimensional ratio in the range 1.8 to 5.3, preferably 3±0.7, and a process for producing them. 1. A process for preparing maltitol crystals having a rectangular parallelepipedal shape and a ratio of length to width dimensions being in the range 1.8 to 5.3 , wherein a maltitol syrup is crystallized in water in the presence of impurities constituted by aldehydes and condensed dicarbonyl compounds , and maltitol crystals recovered have rectangular parallelepipedal shape and a ratio of length to width dimensions being in the range 1.8 to 5.3.2. The process according to claim 1 , wherein the maltitol crystals have a ratio of length to width dimensions is in the range of 2.3 to 3.7.3. The process according to claim 1 , wherein the impurities are present in a quantity less than 5%.4. The process according to claim 3 , wherein the impurities are present in a quantity in the range 1.5% to 4.5%.5. The process according to claim 4 , wherein the impurities the impurities are present in a quantity in the range 2.5% to 3.5%.6. The process according to claim 1 , wherein the aldehydes and the condensed dicarbonyl compounds are obtained by a heat treatment at more than 100° C. of glucidic solutions selected from the group consisting of saccharose claim 1 , fructose claim 1 , invert sugars and glucose syrups.7. The process according to claim 1 , wherein the process comprises:a) preparing a first maltitol syrup with a dry matter content of at least 60% by weight and with a maltitol content of at least 85% by weight;b) introducing into said maltitol syrup a sugar selected from the group constituting of saccharose, fructose, invert sugars, and glucose syrups, used alone or as a mixture;c) heating said first maltitol syrup in order to generate impurities constituted by aldehydes and condensed dicarbonyl compounds;d) preparing a second maltitol syrup ...

Подробнее
07-02-2019 дата публикации

Rhamnolipid Amides For Hair Scent Retention

Номер: US20190040095A1
Принадлежит: EVONIK DEGUSSA GmbH

The invention provides derivatives of rhamnolipids, formulations comprising these, and the use thereof. 1. A rhamnolipid amide.3. The rhamnolipid amide according to claim 2 , wherein Ris selected from the group consisting of the alkyl radicals.5. The rhamnolipid amide according to claim 2 , wherein the radical —NRRis derived from an amine NHRRselected from amino acids and peptides.6. A process for the preparation of rhamnolipid amides comprising the process stepsA) providing a rhamnolipid,B) reacting the rhamnolipid with at least one coupling reagent,C) reacting the rhamnolipid activated by process step B) with an amine, and optionallyD) purifying ourthe rhamnolipid amide.7. The process according to claim 6 , wherein in process step B) the coupling reagent used is at least one selected from the group consisting on dicyclohexylcarbodiimide claim 6 , diisopropylcarbodiimide claim 6 , 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride claim 6 , N-cyclohexyl-N′-(2′-morpholinoethyl)carbodiimide metho-p-toluenesulphonate claim 6 , N-benzyl-N′-3′ dimethylaminopropylcarbodiimide hydrochloride claim 6 , 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide claim 6 , N-ethylcarbodiimide hydrochloride and carbonyldiimidazole.8. The process according to claim 6 , wherein in process step C) at least one catalyst selected from the the group consisting of N-ethyldiisopropylamine claim 6 , trialkylamines claim 6 , pyridine claim 6 , 4-dimethylaminopyridine and hydroxybenzotriazole.9. The rhamnolipid amide obtainable by a process according to .10. A formulation claim 1 , in particular a cosmetic one claim 1 , comprising at least one rhamnolipid amide according to .11. A hair fragrance comprising the rhamnolipid amide according to .12. The rhamnolipid amide according to claim 2 , wherein Ris selected from the group consisting of the alkyl radicals having amine groups and having 4 to 8 carbon atoms.13. The rhamnolipid amide according to claim 2 , wherein Ris H.14. The rhamnolipid ...

Подробнее
16-02-2017 дата публикации

METHOD FOR SYNTHESIS OF REACTIVE CONJUGATE CLUSTERS

Номер: US20170043025A1
Принадлежит: Ionis Pharmaceuticals, Inc.

Provided herein are improved methods for the synthesis of reactive conjugate clusters and intermediates used in such methods. In particular, improvements are provided that enhance the synthesis of reactive conjugate clusters by reducing the number of synthetic steps required. The reactive conjugate clusters prepared using the improved methods don't include any transacylation impurities that are formed using existing methods. The improved methods also provide an increase in overall yield and a cost benefit over existing methods. 2. The method of wherein each E is Cto Calkyl.3. The method of any of wherein each E is a single bond.4. The method of wherein G is Cto Calkyl optionally including one or more groups selected from —O— claim 1 , —N(H)— and C(═O).5. The method of wherein G is —C(═O)—(CH)—C(═O)—O—.6. The method of wherein G is single bond.7. (canceled)8. The method of wherein Pgis benzyl.1011-. (canceled)12. The method of wherein m is 3.14. The method of wherein the pentafluorophenyl ester protected branching group is at least about 95% pure.1729-. (canceled)30. The method of wherein the pentafluorophenyl ester protected branching group and about 3.4 equivalents of the functionalized ligand are dissolved in the organic solvent and Pd(OH)/C is added under Hwith stirring at room temperature until completion.31. The method of wherein the organic solvent is acetonitrile claim 1 , ethyl acetate claim 1 , tetrahydrofuran or a mixture thereof.32. The method of wherein the organic solvent is tetrahydrofuran.33. The method of wherein the reactive conjugate cluster is prepared without using column chromatography.3536-. (canceled)37. The method of further comprising treatment of the reactive conjugate cluster with pentafluorophenyl trifluoroacetate to provide a PFP esterified conjugate cluster.38. The method of wherein the PFP esterified conjugate cluster is prepared without using column chromatography.39. The method of wherein the PFP esterified conjugate cluster is ...

Подробнее
15-02-2018 дата публикации

A METHOD OF SEPARATING RHAMNOLIPIDS FROM A FERMENTATION BROTH

Номер: US20180044364A1
Принадлежит: CONOPCO, INC., D/B/A UNILEVER

A method of extracting at least one rhamnolipid compound from a rhamnolipid fermentation mixture, the method comprising the steps of: (a) admixing an inert adsorbing support with a rhamnolipid fermentation mixture; (b) dissolving the mixture in an organic solvent at a temperature higher than 31° C. and at a pressure higher than 73 bars; (c) separating at least one fatty compound; (d) adding a co-solvent to said organic solvent; (e) modifying temperature and/or pressure; (f) separating a first rhamnolipid compound; and (g) separating a second rhamnolipid compound. 1. A method of extracting at least one rhamnolipid compound from a rhamnolipid fermentation mixture , the method comprising the steps of:(a) admixing an inert adsorbing support with a rhamnolipid fermentation mixture;(b) dissolving the mixture in an organic solvent at a temperature higher than 31° C. and at a pressure higher than 73 bars;(c) separating at least one fatty compound;(d) adding a co-solvent to said organic solvent;(e) modifying temperature and/or pressure;(f) separating a first rhamnolipid compound; and(g) separating a second rhamnolipid compound.2. A method according to wherein the rhamnolipid extraction of steps (f) and (g) follows addition of a co-solvent (d) and increase in temperature and/or pressure in step (e).3. A method according to wherein the defatting step (c) precedes steps (d) to (f).4. A method according to wherein the steps are alphabetically sequential.5. (canceled)6. A method according to wherein the first rhamnolipid compound comprises a mono-rhamnolipid.7. A method according to wherein the second rhamnolipid compound comprises a di-rhamnolipid.8. A method according to wherein the inert adsorbing support comprises diatomaceous earth.9. A method according to wherein the organic solvent is carbon dioxide.10. A method according to wherein the organic solvent is in the supercritical state.11. A method according to wherein the organic solvent is in a supercritical state throughout ...

Подробнее
19-02-2015 дата публикации

OLIGOSACCHARIDES COMPRISING AN AMINOOXY GROUP AND CONJUGATES THEREOF

Номер: US20150050262A1
Принадлежит: Genzyme Corporation

The invention provides methods for the synthesis of oligosaccharides comprising an aminooxy group. The invention further provides oligosaccharides comprising an aminooxy group, methods for coupling oligosaccharides comprising an aminooxy group to glycoproteins, and oligosaccharide-protein conjugates. Also provided are methods of treating a lysosomal storage disorder in a mammal by administration of an oligosaccharide-protein conjugate. 155-. (canceled)60. The method of claim 59 , wherein step (c) comprises reacting the first reactive group of the oligosaccharide with the second reactive group of the aminooxy compound in the presence of a coupling reagent and/or a catalyst.63. The method of claim 62 , wherein Y is a hydrazine claim 62 , hydrazide claim 62 , aminooxy claim 62 , thiosemicarbazide claim 62 , semicarbazide claim 62 , or amine group.65. The method of claim 64 , wherein step (c) comprises reacting the first reactive group of the oligosaccharide with the second reactive group of the aminooxy compound in the presence of a coupling reagent and/or a catalyst.66. The method of claim 65 , wherein the coupling reagent is 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide (EDC) and the catalyst is N-hydroxysuccinimide (NHS).68. The method of claim 67 , wherein the protein is a glycoprotein and the at least one carbonyl group is obtained by oxidation of the glycoprotein with periodate.69. The method of claim 67 , wherein the protein is a lysosomal enzyme.70. The method of claim 69 , wherein the lysosomal enzyme is acid α-glucosidase claim 69 , α-galactosidase A claim 69 , acid sphinogyelinase claim 69 , or α--iduronidase.71. The method of claim 69 , wherein the lysosomal enzyme is acid α-glucosidase.72. The method of claim 67 , wherein m is 3.73. The method of claim 67 , wherein p is 1.74. The method of claim 67 , wherein m is 3 and p is 1.75. The method of claim 74 , wherein the protein is acid α-glucosidase.76. An oligosaccharide-protein conjugate produced by the ...

Подробнее
19-02-2015 дата публикации

METHOD FOR TREATING LOCALIZED FAT DEPOSITS

Номер: US20150051162A1
Автор: LEIGHTON Anton
Принадлежит:

The present invention is directed to methods for treating obesity, reducing excessive body weight, treating an obesity-related condition, treating unwanted localized fat deposits, and treating areas of cellulite. The method comprises the steps of first identifying a subject in need thereof, and administering to the subject an effective amount of rhamnolipids. A pharmaceutical composition comprising rhamnolipids can be applied by any accepted mode of administration including oral, intranasal, subcutaneous, percutaneous, intravenous, or intracutaneous administration. 15-. (canceled)6. A method for treating unwanted localized fat deposits in a mammal subject , comprising the steps of:identifying a subject suffering from localized fat deposits, andadministering into or around the areas of localized fat deposits of the subject an effective amount of rhamnolipids, whereby the local fat deposits are reduced.7. The method according to claim 6 , wherein said subject suffers from lipodystrophy or lipoma.9. The method according to claim 6 , wherein said rhamnolipids are α-L-rhamnosyl-β-hydroxydecanoyl-β-hydroxydecanoate claim 6 , α-L-rhamnosyl-(1 claim 6 ,2)-α-L-rhamnosyl-β-hydroxydecanoyl-β-hydroxydecanoate claim 6 , or the combination thereof.10. The method according to claim 6 , which is in a form suitable for subcutaneous claim 6 , percutaneous claim 6 , or intracutaneous administration.1115-. (canceled)16. A method for treating areas of cellulite in a human subject claim 6 , comprising the steps of:identifying a human subject suffering from cellulite, andadministering into or around the areas of cellulite an effective amount of rhamnolipids, whereby the appearance of cellulite is improved18. The method according to claim 16 , wherein said rhamnolipids are α-L-rhamnosyl-β-hydroxydecanoyl-β-hydroxydecanoate claim 16 , α-L-rhamnosyl-(1 claim 16 ,2)-α-L-rhamnosyl-β-hydroxydecanoyl-β-hydroxydecanoate claim 16 , or the combination thereof.19. The method according to claim 16 , ...

Подробнее
13-02-2020 дата публикации

Method for preparing surfactant compositions comprising alkyl liduronamides d-glucuronamides and l-rhamnosides from ulvans

Номер: US20200045962A1
Принадлежит: ÉCOLE NATIONALE SUPÉRIEURE DE CHIMIE

The present invention relates to a novel process for preparing surfactant compositions based on alkyl L-iduronamides, alkyl L-rhamnosides and alkyl D-glucuronamides, to the compositions obtained via said process and to the uses thereof.

Подробнее
25-02-2016 дата публикации

NOVEL PROCESS FOR PREPARING POLYOL GLYCOSIDES

Номер: US20160052950A1
Принадлежит:

A process for preparing a composition (C) represented by the formula (I): HO—CH—(CHOH)—CH—O-(G)-H, in which G represents the remainder of a reducing sugar, n is an integer equal to 2, 3 or 4 and x, which indicates the mean degree of polymerization of the remainder G, represents a decimal number greater than 1 and less than or equal to 5, characterized in that the process includes at least one step a) of reacting a polyol of formula (A): HO—CH—(CHOH)—CH—OH, in which n is an integer equal to 2, 3 or 4, with a reducing sugar of formula (II): HO-G-H, in which G represents the remainder of a reducing sugar, in the presence of an acid catalyst (C), and in that the acid catalyst (C) is chosen from phosphorous acid, phosphoric acid and polyphosphoric acid. 1. A process for the preparation of a composition (C) represented by the formula (I):{'br': None, 'sub': 2', 'n', '2', 'x, 'HO—CH—(CHOH)—CH—O-(G)-H\u2003\u2003(I),'}{'sub': '1', 'claim-text': {'br': None, 'sub': 2', 'n', '2', '1, 'HO—CH—(CHOH)—CH—OH\u2003\u2003(A),'}, 'in which G represents the residue of a reducing sugar, n is an integer equal to 2, 3 or 4 and x, which indicates the mean degree of polymerization of said residue G, represents a decimal number greater than 1 and less than or equal to 5, characterized in that said process comprises at least one stage a) of reaction of a polyol of formula (A) {'br': None, 'HO-G-H\u2003\u2003(II)'}, 'in which n is an integer equal to 2, 3 or 4, with a reducing sugar of formula (II){'sub': a', 'a, 'in which G represents the residue of a reducing sugar, in the presence of an acid catalyst (C), and in that said acid catalyst (C) is chosen from hypophosphorous acid, phosphoric acid and polyphosphoric acid.'}2. The process as defined in claim 1 , characterized in that claim 1 , in the formulae (I) and (II) claim 1 , said residue G of a reducing sugar is chosen from the residues of glucose claim 1 , xylose and arabinose.3. The process as defined in claim 1 , characterized in that ...

Подробнее
25-02-2021 дата публикации

CONJUGATED ANTISENSE COMPOUNDS AND THEIR USE

Номер: US20210054017A1
Принадлежит:

Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine anaologues. 1243-. (canceled)247. The compound of claim 245 , wherein Qis CH.248. The compound of claim 244 , wherein Ris CHN.249. The compound of claim 248 , wherein Qis CH.252. The compound of claim 250 , wherein Ris CHOH.254. The compound of wherein L comprises a phosphorus linking group claim 244 , NH claim 244 , or N(CH).256. The compound of claim 244 , wherein the oligomer is a modified oligonucleotide comprising at least one modified nucleoside comprising a modified base and/or a modified sugar moiety.257. The compound of having at least one modified nucleoside comprising a modified sugar moiety selected from a bicyclic sugar moiety and a 2′-substituted sugar moiety.258. The compound of claim 257 , comprising at least one 4′-C(CH)H—O-2′ or 4′-CH—O-2′bridged bicyclic sugar moiety.259. The compound of comprising at least one 2′-O(CH)OCHsubstituted sugar moiety.260. The compound of claim 244 , wherein the conjugate group is attached to the 5′-terminal nucleoside of the oligomer.261. The compound of claim 244 , wherein the conjugate group is attached to the 3′-terminal nucleoside of the oligomer.262. The compound of claim 244 , wherein the oligomer is an oligonucleotide and has a sugar motif comprising:a 5′-region consisting of 2-8 linked 5′-region nucleosides, wherein at least two 5′-region nucleosides are modified nucleosides and wherein the 3′-most 5′-region nucleoside is a modified nucleoside;a 3′-region consisting of 2-8 linked 3′-region nucleosides, wherein at least two 3′-region nucleosides are modified nucleosides and wherein the 5′-most 3′-region nucleoside is a modified nucleoside; anda central region between the 5′-region and the 3′-region consisting of 5-10 linked central region nucleosides, each independently selected from among: a modified nucleoside and an unmodified ...

Подробнее
13-02-2020 дата публикации

ENTEROCOCCUS FAECALIS AND/OR ENTEROCOCCUS FAECIUM ANTIGEN

Номер: US20200048296A1
Принадлежит:

The present invention generally relates to the field of detecting and preventing infectious diseases caused by and/or . More specifically, the invention relates to an and/or antigen which comprises at least one unit having the following general formula: 2. The method of claim 1 , wherein the animal is a mammal.3. The method of claim 1 , wherein each of the two sugar moieties in the antigen is in the D configuration.4. The method of claim 1 , wherein the disaccharide moieties in the antigen consist of a furanose Gal and a pyranose Glc and wherein the antigen has a structure selected from the following:→-v)-D-Galf-(1→-z)-D-Glcp-(1→-,→-v)-D-Galf-(1→-z)-D-Glcf-(1→-,→-v)-D-Galp-(1→-z)-D-Glcp-(1→-, or→-v)-D-Galp-(1→-z)-D-Glcf-(1→-,wherein v and z are in each case 1, 2, 3, 4, 5 or 6.5. The method of claim 1 , wherein in the antigen: R1 is OH claim 1 , X is O claim 1 , Y is O claim 1 , and CA is lactyl.6. The method of claim 1 , wherein the antigen is bound to a pharmaceutically acceptable immunosupport.7. The method of claim 1 , further comprising isolating from the animal a DNA sequence that encodes for the antibody or a fragment of the antibody and expressing the DNA sequence in a cell to produce the antibody or a fragment of the antibody.8. The method of claim 7 , wherein the cell is a bacterium or a eukaryotic cell.9Escherichia coli.. The method of claim 8 , wherein the bacterium is10. The method of claim 8 , wherein the eukaryotic cell is a Chinese hamster ovary cell.12. The method of claim 11 , wherein the animal is a mammal.13. The method of claim 11 , wherein each of the two sugar moieties in the antigen is in the D configuration.14. The method of claim 11 , wherein the disaccharide moieties in the antigen consist of a furanose Gal and a pyranose Glc and wherein the antigen has a structure selected from the following:→-v)-D-Galf-(1→-z)-D-Glcp-(1→-,→-v)-D-Galf-(1→-z)-D-Glcf-(1→-,→-v)-D-Galp-(1→-z)-D-Glcp-(1→-, or→-v)-D-Galp-(1→-z)-D-Glcf-(1→-,wherein v and z are in ...

Подробнее
04-03-2021 дата публикации

ASIALOGLYCOPROTEIN RECEPTOR MEDIATED DELIVERY OF THERAPEUTICALLY ACTIVE CONJUGATES

Номер: US20210060168A1
Принадлежит:

ASGP-R binding molecular conjugates are provided. The conjugates are useful to deliver therapeutically effective amounts of biologically active molecules to target cells and tissues of a subject. Compositions are also provided comprising the molecular conjugates. 2. The compound of claim 1 , wherein X claim 1 , Xand Xare each independently (—CH)—O—CH— claim 1 , wherein m is 1-4.3. (canceled)4. The compound of claim 1 , wherein Y claim 1 , Yand Yare each independently —NHC(O)— or —C(O)NH—.5. (canceled)6. The compound of claim 1 , wherein L claim 1 , Land Lare each independently C-Calkyl or —(CH—CH—O)(CH)— claim 1 , wherein k is 1-10.7. The compound of claim 1 , wherein L claim 1 , Land Lare each independently —(CH—CH—O)(CH)— claim 1 , wherein k is 2-4.8. The compound of claim 1 , wherein L claim 1 , Land Lare each independently C-Calkyl.9. The compound of claim 1 , wherein G claim 1 , Gand Gare each independently selected from the group consisting of folic acid claim 1 , ribose claim 1 , retinol claim 1 , niacin claim 1 , riboflavin claim 1 , biotin claim 1 , glucose claim 1 , mannose claim 1 , fucose claim 1 , sucrose claim 1 , lactose claim 1 , mannose-6-phosphate claim 1 , N-acetyl galactosamine claim 1 , N-acetylglucosamine claim 1 , a sialic acid claim 1 , a sialic acid derivative claim 1 , allose claim 1 , altrose claim 1 , arabinose claim 1 , cladinose claim 1 , erythrose claim 1 , erythrulose claim 1 , fructose claim 1 , fucitol claim 1 , fucosamine claim 1 , fucose claim 1 , fuculose claim 1 , galactosamine claim 1 , galactosaminitol claim 1 , galactose claim 1 , glucosamine claim 1 , glucosaminitol claim 1 , glucose-6 phosphate claim 1 , gulose glyceraldehyde claim 1 , glycero-mannosheptose claim 1 , glycerol claim 1 , glycerone claim 1 , gulose claim 1 , idose claim 1 , lyxose claim 1 , mannosamine claim 1 , psicose claim 1 , quinovose claim 1 , quinovosamine claim 1 , rhamnitol claim 1 , rhamnosamine claim 1 , rhamnose claim 1 , ribulose claim 1 , ...

Подробнее
03-03-2016 дата публикации

THIOSACCHARIDE MUCOLYTIC AGENTS

Номер: US20160060284A1
Принадлежит:

There are provided, inter alia, methods for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof, the methods including administering to the subject an effective amount of a thiosaccharide mucolytic agent, and compounds and pharmaceutical compositions useful for the methods. 1. A method for decreasing mucus elasticity or decreasing mucus viscosity in a subject in need thereof , said method comprising administering to said subject in need thereof an effective amount of a thiosaccharide mucolytic agent.25.-. (canceled)7. The method of claim 6 , wherein R claim 6 , R claim 6 , Rand Rare —OH;{'sup': '1', 'Ris H;'}{'sup': '2A', 'sub': 1', '10, 'Ris an unsubstituted C-Cthiol-alkyl or unsubstituted 2 to 10 membered thiol-heteroalkyl;'}{'sup': 2B', '2C, 'sub': 1', '10, 'Ris —C(O)R, unsubstituted C-Cthiol-alkyl or unsubstituted thiol-heteroalkyl; and'}{'sup': '2C', 'sub': 1', '10, 'Ris substituted or unsubstituted C-Cthiol-alkyl or substituted or unsubstituted 2 to 10 membered thiol-heteroalkyl.'}812.-. (canceled)13. The method of claim 6 , wherein R claim 6 , R claim 6 , Rare —OH.1418.-. (canceled)19. The method of claim 6 , wherein{'sup': 3', '4', '5, 'R, Rand Rare —OH; and'}R5′ is H.2026.-. (canceled)27. The method of claim 6 , wherein Ris —SH.2830.-. (canceled)31. The method of claim 6 , wherein{'sup': '5', 'Ris —SH; and'}{'sup': '5′', 'Ris H.'}3234.-. (canceled)35. The method of claim 6 , wherein{'sup': 1', '1A, 'Ris —OR;'}{'sup': 2', '3', '4, 'R, R, and Rare —OH;'}{'sup': 5', '5A, 'Ris H or —OR; and'}{'sup': '5′', 'Ris H.'}3649.-. (canceled)50. The method of claim 6 , wherein{'sup': 1', '1A, 'Ris —OR;'}{'sup': 2', '3', '4, 'R, R, and Rare —OH;'}{'sup': '5′', 'Ris H; and'}{'sup': '5', 'Ris —SH.'}5153.-. (canceled)54. The method of claim 6 , wherein{'sup': 1', '1A, 'Ris —OR;'}{'sup': 2', '3', '4, 'R, R, and Rare —OH;'}{'sup': '5', 'Ris —SAc; and'}{'sup': '5′', 'Ris H.'}55. (canceled)56. The method of claim 6 , wherein{'sup': 1', '1A', ' ...

Подробнее
02-03-2017 дата публикации

Carbon-Based Fluorescent Tracers as Oil Reservoir Nano-Agents

Номер: US20170058192A1
Принадлежит:

The present invention relates to carbon-based fluorescent nano-agent tracers for analysis of oil reservoirs. The carbon-based fluorescent nano-agents may be used in the analysis of the porosity of a formation. The nanoagents are suitable for injection into a petroleum reservoir and may be recovered from the reservoir for the determination of hydrocarbon flow rates and retention times. 1. A fluorescent nanoagent for use in a subsurface petroleum reservoir , the nanoagent comprising:a carbon-based nanoparticle core, said nanoparticle core having an average diameter of less than about 100 nm;wherein said nanoparticle core includes a plurality of functional groups appended to the surface thereof; andwherein the fluorescent nanoagent is produced from a solution comprising a sugar, an amino alcohol and deionized water reacted under conditions capable of synthesizing the fluorescent nanoagent.2. The fluorescent nanoagent of claim 1 , wherein the carbon-based nanoparticle core has an average diameter of less than about 75 nm.3. The fluorescent nanoagent of claim 1 , wherein the fluorescent nanoagent is detectable at a concentration of about 0.01 ppm.4. The fluorescent nanoagent of claim 1 , wherein the functional groups appended the surface of the fluorescent nanoagent can be excited at a wavelength between about 400 nm and 500 nm.5. The fluorescent nanoagent of claim 1 , wherein the functional group appended to the surface of the nanoparticle core is an amino alcohol.6. The fluorescent nanoagent of claim 1 , wherein the functional group appended to the surface of the nanoparticle core is selected from methanolamine claim 1 , ethanolamine claim 1 , and propanolamine.7. The fluorescent nanoagent of claim 1 , wherein the functional group appended to the surface of the nanoparticle core is ethanolamine.8. The fluorescent nanoagent of claim 1 , wherein the functional group is appended to the surface of the nanoparticle core is appended with an amide linkage.9. The fluorescent ...

Подробнее
05-03-2015 дата публикации

SULFATED OLIGOSACCHARIDE DERIVATIVES

Номер: US20150065440A1
Принадлежит:

The invention relates to novel compounds that have utility as inhibitors of heparan sulfate-binding proteins; compositions comprising the compounds, and use of the compounds and compositions thereof for the antiangiogenic, antimetastatic, anti-inflammatory, antimicrobial, anticoagulant and/or antithrombotic treatment of a mammalian subject. 2. The pharmaceutical or veterinary composition according to claim 1 , wherein in said at least one compound Ris cholestanyl.3. The pharmaceutical or veterinary composition according to claim 1 , wherein in said at least one compound Ris propylstearamide.4. The pharmaceutical or veterinary composition according to claim 1 , wherein said at least one compound is selected from the group consisting of:{'smallcaps': D', 'D', 'D', 'D, '3β-cholestanyl-2,3,4,6-tetra-O-sodium sulfonato-α--glucopyranosyl-(1→4)-2,3,6-tri-O-sodium sulfonato-α--glucopyranosyl-(1→4)-2,3,6-tri-O-sodium sulfonato-α--glucopyranosyl-(1→4)-2,3,6-tri-O-sodium sulfonato-β--glucopyranoside (compound 65);'}{'smallcaps': D', 'D', 'D, '4-(cholestan-3β-yl-oxymethyl)[1,2,3]triazol-1-yl-2,3,4,6-tetra-O-sodium sulfonato-α--glucopyranosyl-(1→4)-2,3,6-tri-O-sodium sulfonato-α--glucopyranosyl-(1→4)-1-deoxy-2,3,6-tri-O-sodium sulfonato-β--glucopyranoside (compound 70);'}{'smallcaps': D', 'D', 'D, '4-(cholestan-3β-yl-oxymethyl)[1,2,3]triazol-1-yl-2,3,4,6-tetra-O-sodium sulfonato-α--glucopyranosyl-(1→4)-2,3,6-tri-O-sodium sulfonato-α--glucopyranosyl-(1→4)-1-deoxy-2,3,6-tri-O-sodium sulfonato-β--glucopyranoside (compound 76);'}{'smallcaps': D', 'D', 'D, '3β-cholestanyl-2,3,4,6-tetra-O-sodium sulfonato-α--glucopyranosyl-(1→4)-2,3,6-tri-O-sodium sulfonato-α--glucopyranosyl-(1→4)-2,3,6-tri-O-sodium sulfonato-β--glucopyranoside (compound 87);'}{'smallcaps': D', 'D', 'D, '3-stearamidopropyl-2,3,4,6-tetra-O-sulfo-α--glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-α--glucopyranosyl-(1→4)-2,3,6-tri-O-sulfo-β--glucopyranoside, decasodium salt (compound 123); and'}{'smallcaps': D', 'D', 'D', 'D, '3- ...

Подробнее
22-05-2014 дата публикации

SYNTHESIS OF CARBOHYDRATE-BASED SURFACTANTS

Номер: US20140142287A1

The present invention provides carbohydrate-based surfactants and methods for producing the same. Methods for producing carbohydrate-based surfactants include using a glycosylation promoter to link a carbohydrate or its derivative to a hydrophobic compound. 1. A method for producing a carbohydrate- or its derivative-based surfactant , said method comprising contacting a carbohydrate or its derivative with a hydrophobic compound in the presence of a catalytic amount of a glycosylation promoter under conditions sufficient to form a covalent bond between said carbohydrate or its derivative and said hydrophobic compound to produce a carbohydrate- or its derivative based surfactant , wherein said hydrophobic compound comprises a functional group selected from the group consisting of an amine group , a hydroxyl group and a thiol group , and wherein the functional group of said hydrophobic compound covalently links said hydrophobic compound to said carbohydrate or its derivative.2. The method of claim 1 , wherein said glycosylation promoter comprises a bismuth (III) compound claim 1 , a scandium (III) compound claim 1 , a boron compound claim 1 , an indium (III) compound or a mixture thereof3. The method of claim 2 , wherein said glycosylation promoter comprises a bismuth (III) compound.4. The method of claim 3 , wherein said bismuth (III) compound comprises bismuth trifluoromethanesulfonate claim 3 , bismuth halide claim 3 , or a mixture thereof.5. The method claim 1 , wherein the amount of glycosylation promoter used in the reaction is about 0.25 equivalent or less.6. The method of claim 1 , wherein said hydrophobic compound is a hydrocarbon compound of the formula R—X claim 1 , wherein Ris a hydrocarbon and X is —OH claim 1 , —NH claim 1 , or —SH.7. The method of claim 6 , wherein Rx is a C-Chydrocarbon.8. The method of claim 7 , wherein Rx is a C-Chydrocarbon.12. The carbohydrate-based surfactant according to claim 11 , wherein x is 6 claim 11 , 10 claim 11 , 12 or 14. ...

Подробнее
22-05-2014 дата публикации

Process for the preparation of (2r,3s)-2-(hydroxymethyl)-5-methoxytetrahydrofuran-3-ol and acetylated derivatives thereof, free of pyranose compounds

Номер: US20140142296A1
Автор: Albercht Zumbrunn, Xing FU
Принадлежит: JOHNSON MATTHEY PLC

The invention provides methyl-2-deoxyriboside containing at most 5 wt % of methyl-2-deoxyribopyranoside, based on the combined weight of methyl-2-deoxyriboside and methyl-2-deoxyribopyranoside.

Подробнее
28-02-2019 дата публикации

ELEMENTAL SULFUR DISPERSANT TO CONTROL FOULING IN WATER SYSTEMS

Номер: US20190062184A1
Принадлежит: ECOLAB USA, Inc.

A composition and method for dispersing sulfur, cleaning sulfur deposits, and minimizing foaming in an aqueous system is disclosed. The method may include adding a first sulfur dispersant to process water containing sulfur and dispersing the sulfur. The first sulfur dispersant may include a C-Calkyl polyglycoside. A second sulfur dispersant may also be added to the process water. The second sulfur dispersant may include a polymer of acrylic acid and 2-acrylamido-2-methylpropane sulfonic acid. 1. A method of dispersing sulfur , comprising:{'sub': 5', '25, 'adding a first sulfur dispersant to process water containing sulfur, wherein the first sulfur dispersant comprises a C-Calkyl polyglycoside; and'}dispersing the sulfur.2. The method of claim 1 , further comprising adding a second sulfur dispersant to the process water.3. The method of claim 2 , wherein the second sulfur dispersant comprises a polymer comprising acrylic acid and 2-acrylamido-2-methylpropane sulfonic acid.4. The method of claim 2 , further comprising blending the first sulfur dispersant and the second sulfur dispersant to form a dispersant mixture before addition to the process water.5. The method of claim 4 , wherein the dispersant mixture comprises from about 5% to about 95% by weight of the first sulfur dispersant and from about 95% to about 5% by weight of the second sulfur dispersant.6. The method of claim 1 , further comprising adding an anti-foaming agent to the process water.7. The method of claim 6 , wherein the anti-foaming agent is selected from a C-Calkyl alcohol claim 6 , a C-Calkyl alcohol ethoxylate claim 6 , monobasic aluminum stearate claim 6 , stearic acid claim 6 , polydimethylsiloxane claim 6 , sorbitan monostearate claim 6 , hydrated silica claim 6 , ethoxylated sorbitan monostearate claim 6 , xanthan gum claim 6 , amorphous silica claim 6 , and any combination thereof.8. The method of claim 6 , wherein the anti-foaming agent comprises polydimethylsiloxane and sorbitan ...

Подробнее
28-02-2019 дата публикации

Process for preparing compositions comprising alkyl(alkyl-glucoside)uronates, said compositions and use thereof as a surfactant

Номер: US20190062360A1
Принадлежит: ÉCOLE NATIONALE SUPÉRIEURE DE CHIMIE

The present invention relates to a novel process for preparing compositions comprising alkyl(alkyl-glucoside)uronates, from biobased or biocompatible/biodegradable raw materials, and also salts and acids thereof.

Подробнее
28-02-2019 дата публикации

METHOD FOR OBTAINING SURFACTANT COMPOSITIONS MADE FROM ALKYL-L-GULURONAMIDES

Номер: US20190062362A1
Принадлежит: ÉCOLE NATIONALE SUPÉRIEURE DE CHIMIE

Some embodiments relate to a novel method for obtaining surfactant compositions made from alkyl-L-guluronamides or mixtures of L-guluronamides and D-mannuronamides, the compositions obtained by the method and the uses thereof. 2. The process as claimed in claim 1 , further including performing of neutralizing the reaction medium derived from the butanolysis and Fischer glycosylation reaction before the aminolysis reaction.3. The process as claimed in claim 1 , wherein the butanolysis and Fischer glycosylation reaction is performed in the presence of:(i) water and/or of an ionic solvent and/or of a eutectic solvent,(ii) a linear or branched, saturated or unsaturated alcohol of the formula ROH, containing from 1 to 4 carbon atoms, and(iii) an acid catalyst.4. The process as claimed in claim 3 , wherein the acid catalyst is selected from the group consisting of consisting of: hydrochloric acid claim 3 , sulfuric acid claim 3 , an alkylsulfuric acid claim 3 , a sulfonic acid claim 3 , an alkylsulfonic acid or an alkyl sulfosuccinate claim 3 , perhalohydric acids claim 3 , metals claim 3 , oxides thereof or salts thereof such as the halides thereof.5. The process as claimed in claim 4 , wherein the acid catalyst is methanesulfonic acid.6. The process as claimed in claim 3 , wherein the alcohol ROH is n-butanol.7. The process as claimed in claim 1 , wherein the aminolysis reaction is performed in the presence of a fatty amine selected from the group consisting of dodecylamine and oleylamine.8. A composition obtained via the process as claimed in .9. The composition as claimed in claim 8 , wherein the composition is an oil-in-water or water-in-oil emulsion.10. The use of the composition as claimed in as a surfactant.11. The use of a composition as claimed in claim 10 , wherein the surfactant is selected from the group consisting of solubilizers claim 10 , hydrotropes claim 10 , wetting agents claim 10 , foaming agents claim 10 , emulsifying agents claim 10 , emulsifiers ...

Подробнее
17-03-2022 дата публикации

ACIDIC DYSTROGLYCAN OLIGOSACCHARIDE COMPOUND AND METHOD FOR MAKING SAME

Номер: US20220081463A1
Принадлежит:

A synthetic dystroglycan oligosaccharide comprising: The present application claims the benefit of provisional patent application U.S. patent application Ser, No. 62/614,173 entitled “METHOD FOR SYNTHETIC ASSEMBLY OF ACIDIC DYSTROGLYCAN OLIGOSACCHARIDES” and filed Jan. 5, 2018, the entirety of which is incorporated herein by reference for all purposes.The present disclosure generally relates to dystroglycan oligosaccharide compounds and methods for synthetic assembly of the same.The field of glycoscience explores the structures and functions of carbohydrates that calls for the rapid access of structurally defined oligosaccharides. In contrast to the synthesis of nucleic acids and peptides/proteins, synthetic preparation of carbohydrates remains a laborious process that necessitates the development of novel yet robust synthetic strategy to achieve automated oligosaccharide synthesis.1.1 Structure and Biological Importance of Dystrophin-glycoprotein ComplexMuscular dystrophies (MDs) are a group of genetic muscle diseases that cause muscle weakness and result in a multi-system disorder in the heart, nervous system, eyes and brain. Dystrophin-glycoprotein complex (DGC)(), a multimeric transmembrane protein and glycoprotein complex is known to be involved in these diseases.An important component of DGC is dystroglycan (DG), which connects the extracellular matrix and cytoskeleton. DG plays a critical role in organizing extracellular matrix molecules on the cell surface and in basement membranes to keep muscle membrane integrity. DG has been found in all vertebrate tissuesand was originally isolated from skeletal muscle as an integral membrane component of the DGC.Glycosylation is the crucial post-translational modification that modulates the function of DG. Interactions between DG and its extracellular binding partners heavily rely on the carbohydrate side chains.DG consists of two subunits, namely α-dystroglycan and β-dystroglycan. Post-translational processing through ...

Подробнее
27-02-2020 дата публикации

Substituted 4-phenyl pyridine compounds as non-systemic tgr5 agonists

Номер: US20200062795A1
Принадлежит: Ardelyx Inc

where R1, R2, R2′, R3, R4, X1, X2, X3, X4, Q, and n are described herein.

Подробнее
11-03-2021 дата публикации

NEW GLYCERYL POLYRHAMNOSIDES, PROCESS FOR THE PREPARATION THEREOF, AND COSMETIC AND/OR PHARMACEUTICAL COMPOSITION COMPRISING SAME

Номер: US20210069084A1
Принадлежит:

Composition based on a polyol of formula HO—CH2-CHOH-CH2-OH and on alkyl polyrhamnosides of formula HO—CH2-CHOH-CH2-O-(Rham)x-H; process for preparing same, and cosmetic or pharmaceutical composition comprising same. 1. A composition (C) comprising , per 100% of mass: {'br': None, 'sub': 2', '2, 'HO—CH—CHOH—CH—OH \u2003\u2003(I);'}, '(1)—an amount of greater than 0% by mass and less than or equal to 50% by mass of a polyol of formula (I){'sub': 'R', 'claim-text': {'br': None, 'sub': 2', '2', 'x, 'HO—CH—CHOH—CH—O-(Rham)-H \u2003\u2003(II),'}, '(2)—from 25% by mass to 95% by mass of a composition (C) represented by formula (II)in which formula (II) Rham represents the rhamnose residue and x, which indicates the average degree of polymerization of said Rham residue, represents a decimal number greater than 1.0 and less than or equal to 2.5;(3)—an amount of greater than 0% by mass and less than or equal to 20% by mass of rhamnose.2. The composition (C) as defined in claim 1 , comprising claim 1 , per 100% of mass:(1)—from 15% to 45% n of glycerol;{'sub': 'R', '(2)—from 30% by mass to 70% by mass of the (C) represented by the formula (II) as defined previously;'}(3)—from 5% to 20% by mass of rhamnose.3. The composition Cas defined in claim 1 , comprising claim 1 , per 100% of mass:(1)—from 5% to 15% n of glycerol;{'sub': 'R', '(2)—from 65% by mass to 85% by mass of the (C) represented by the formula (II) as defined previously;'}(3)—from 3% to 10% by mass of rhamnose.4. A process for preparing the composition (C1) as defined in claim 1 , comprising{'sub': '1', 'a step a) of heating, with gentle stirring, the polyol of formula (I) as defined previously, until the polyol is brought to a higher temperature (T) of at least 5° C. above a melting point of the polyol;'}a step b) of dispersing and homogenizing, with stirring, rhamnose monohydrate[1] in the previously molten medium in the desired stoichiometric ratio;a step c) of acetalization by adding, with stirring, to the ...

Подробнее
09-03-2017 дата публикации

NOVEL SYNTHETIC OLIGOMERS OF NEISSERIA MENINGITIS SEROGROUP X AND PROCESS OF PREPARING THEM

Номер: US20170066794A1
Принадлежит:

The present invention relates to synthesis of novel higher oligomers and process of preparing the same. In particular the present invention relates to the chemical synthesis of oligomers of serogroup X (‘hereinafter Men-X), more particularly tetramer. The present invention provides Men-X capsular oligomers obtained from synthetic pathway using purified saccharides of specific chain length and provides said novel oligomers as candidates for the development of conjugate vaccine against bacterial meningitis caused due to Men-X infections. 1. Novel process of synthesizing oligomers , said process comprising the steps of:synthesizing hemiacetal compd (10)synthesizing propagation unit (12) and terminal unit(s) (14) and (14A)coupling said propagation unit (12) with said terminal unit (14) and coupling said propagation unit (12) with said terminal unit (14A) in the presence of coupling reagents to yield compound (15) and (15A) respectivelyreacting said compounds (15) and (15A) with deacetylating reagents to obtain compounds (16) and (16A) and then coupling compounds (16) and (16A) using said coupling reagents to obtain compounds (17) and (17A)iterative reactions in the presence of said deacetylating reagents and said coupling reagents to yield novel higher synthetic oligomers (18,18A,19,19A,1,1A,X,XA)one step reduction by reductive N-acetylating reagent, deacetylation using said deacetylating reagents and final deprotection of benzyl and Cbz by hydrogenation,such that said process results in novel higher synthetic oligomers (X) and (XA) with better yield, high purity and enhanced efficacy.2. The novel process of synthesizing oligomers as claimed in wherein said novel higher synthetic oligomers (X) and (XA) is tetramer (1) and (1A)3. The novel process of synthesizing oligomers as claimed in wherein the time taken to synthesize said tetramers (1) and (1A) is in the range of 225 hours to 276 hours claim 1 , preferably in 257 hours.4. The novel process of synthesizing oligomers ...

Подробнее
12-03-2015 дата публикации

GLYCOMIMETICS TO INHIBIT PATHOGEN-HOST INTERACTIONS

Номер: US20150072952A1
Принадлежит:

The present invention relates to novel glycomimetic compounds that are rationally designed to inhibit the binding of various pathogens to cell surface sialylated galactose and methods of use thereof. Specifically sialic acid glycosides and C-glycosides are disclosed that form a lactam ring structure or a cyclic ether/amine ring structure with the adjacent monosaccharide residue. 226-. (canceled)28. A glycomimetic compound of claim 27 , wherein P is selected from H claim 27 , OH claim 27 , halogen claim 27 , C-Caliphatic ester claim 27 , C-Caliphatic ether claim 27 , C-Carylether claim 27 , C-Caliphatic ester claim 27 , C-Caryl ester claim 27 , OCH claim 27 , OBenzyl claim 27 , and OCyclohexyl; U is O or CH; V=CH2; W=NH; X=H; Z=OCH3; S=axial OH; R=Ac (CH3C═O); T=OH; and Q=OH.29. A glycomimetic compound of claim 27 , wherein U is selected from C-Caliphatic claim 27 , O claim 27 , NH claim 27 , S claim 27 , or a C-Caliphatic amine; V=CH; W=NH; X=H; Z=OCH claim 27 , S=axial OH; R=Ac (CHC═O); T=OH; Q=OH; and P=OH.30. A glycomimetic compound of claim 27 , wherein U is O or CH; V is selected from a C-Caliphatic; W=NH; X=H or OH; S=axial OH; R=Ac (CHC═O); T=OH; Q=OH; P=OH; and Z=OCH.31. A glycomimetic compound of claim 27 , wherein U=O or CH; V=CH; W is selected from C-Caliphatic claim 27 , O claim 27 , NH claim 27 , S claim 27 , or a C-Caliphatic amine; X=H or OH; S=axial OH; R=Ac (CHC═O); T=OH; Q=OH; Z=OCH; and P=OH.32. A glycomimetic compound of claim 27 , wherein U=O or CH; V=CH; W=NH; X is selected from H claim 27 , OH claim 27 , halogen C-Caliphatic ester claim 27 , C-Caliphatic ether claim 27 , C-Carylether claim 27 , C-Caliphatic ester claim 27 , C-Caryl ester claim 27 , halogen claim 27 , OCH claim 27 , OBenzyl claim 27 , or OCyclohexyl; S=axial OH; R=Ac (CHC═O) claim 27 , T=OH; Q=OH; Z=OCH; and P=OH.33. A glycomimetic compound of claim 27 , wherein U=O or CH; V=CH; W=NH; X=H or OH; S is selected from an axial or equatorial halogen claim 27 , OH claim 27 , H claim ...

Подробнее
09-03-2017 дата публикации

Glycan arrays and method of use

Номер: US20170067885A1
Принадлежит: OBI Pharma Inc

The invention relates to linkers and methods for generating arrays with linkers. The invention also relates to methods for identifying agents that bind to various types of molecules on the arrays and to defining the structural elements of the molecules on the arrays that bind to those agents. The arrays and methods provided herein may be used for epitope identification, drug discovery and as analytical tools. The invention provides useful glycans and epitope determinants that are useful in detecting, diagnosing, recurrence monitoring and preventing cancer.

Подробнее
29-05-2014 дата публикации

PROCESS FOR THE ISOLATION OF RHAMNOLIPIDS

Номер: US20140148588A1
Принадлежит: Evonik Industries AG

A process for isolating rhamnolipids is provided. The process includes providing an aqueous medium containing at least one rhamnolipid and having a pH of less than 6. Next, the aqueous medium is brought into contact with at least one organic solvent to provide a multiphase system and then the aqueous phase is separated off. The pH is then increased to a value of 6 or more to provide a multiphase organic system. Next, a rhamnolipid-enriched organic phase is separated off. An optional step of further purifying the rhamnolipid may be performed. 1. A process for the isolation of rhamnolipids , said process comprising:A) providing an aqueous medium containing at least one rhamnolipid and having a pH of less than 6,B) bringing the aqueous medium into contact with at least one organic solvent to provide a multiphase system and separating off the aqueous phase,C) increasing the pH to a value of 6 or more to provide a multiphase organic system, andD) separating off a rhamnolipid-enriched organic phase2. The process according to claim 1 , wherein the total aqueous medium in process step A) comprises between 10 g/l and 300 g/l of rhamnolipids.3. The process according to claim 1 , wherein said pH of said aqueous medium in process step A) is from 2 to 4.5.4. The process according to claim 1 , wherein the organic solvent or the mixture of the organic solvents of process step B) dissolves water in an amount of from 0.1 to 30% by weight.5. The process according to claim 1 , wherein the at least one organic solvent of process step B) is selected from methyl acetate claim 1 , ethyl acetate claim 1 , propyl acetate claim 1 , isopropyl acetate claim 1 , butyl acetate claim 1 , isoamyl acetate claim 1 , butan-1-ol claim 1 , butan-2-ol and diethyl ether.6. The process according to claim 1 , wherein a volume ratio of said aqueous medium to said organic solvent or to a mixture of the organic solvents prior to bringing them into contact is from 0.2:1 to 5:1.7. The process according to claim ...

Подробнее
29-05-2014 дата публикации

Synthetic Oligosaccharides for Moraxella Vaccine

Номер: US20140148592A1
Принадлежит: SYNGLYCO Inc

The present invention provides synthetic Moraxella catarrhalis lipooligosaccharide (LOS)-based oligosaccharides and conjugates containing various M. catarrhalis serotype-specific oligosaccharide antigens or various core M. catarrhalis oligosaccharide structures or motifs corresponding to one or more of the three major serotypes and/or members within a given serotype. The oligosaccharides may be synthesized by a chemical assembly methodology relying on a limited number of monosaccharide and disaccharide building blocks. The invention further provides M. catarrhalis LOS-based immunogenic and immunoprotective compositions and antibodies derived therefrom for diagnosing, treating, and preventing infections caused by M. catarrhalis.

Подробнее
22-03-2018 дата публикации

Vaccines against carbapenem-resistant klebsiella pneumoniae

Номер: US20180078630A1

The present invention relates to synthetic saccharides of general formula (I): V*—[U x+2 —U x+1 —U x ] n —V—O-L-NH 2 that are related to carbapenem-resistant Klebsiella pneumoniae capsular polysaccharide and conjugates thereof. Said conjugates and pharmaceutical composition containing said conjugates are useful for prevention and/or treatment of diseases associated with carbapenem-resistant Klebsiella pneumoniae . Furthermore, the synthetic saccharides of general formula (I): V*—[U x+2 —U x+1 —U x ] n —V—O-L-NH 2 are useful as marker in immunological assays for detection of antibodies against carbapenem-resistant Klebsiella pneumoniae bacteria.

Подробнее
14-03-2019 дата публикации

NOVEL MANNITOL-BASED AMPHIPATHIC COMPOUND AND USE THEREOF

Номер: US20190077822A1
Принадлежит:

The present invention relates to a mannitol-based amphipathic compound, a method of preparing the same, a method of extracting, solubilizing, stabilizing or crystallizing a membrane protein using the compound, and a method of analyzing a structure of the membrane protein under an electron microscope using the compound. When the mannitol-based compound according to the present invention is used, the membrane protein can be stably stored in an aqueous solution for a prolonged period of time and thus can be applied to analysis of functions and structures thereof. Since the analysis of the structures and functions of the membrane protein is one of the fields of most interest in biology and chemistry currently, and more than half of new drugs currently in development are targeting membrane proteins, the present invention is applicable to research on the structures of membrane proteins closely related to the development of the new drugs. 2. The compound of claim 1 , wherein the saccharide is a monosaccharide or a disaccharide.3. The compound of claim 1 , wherein the saccharide is glucose or maltose.4. The compound of claim 1 , wherein each of Rand Ris a C-Calkyl group; Rand Rare the same; and each of Xto Xis oxygen-linked glucose.6. The compound of claim 1 , wherein the compound is an amphipathic molecule for extracting claim 1 , solubilizing claim 1 , stabilizing or crystallizing a membrane protein.7. The compound of claim 1 , wherein the compound has a critical micellar concentration (CMC) of 1×10mM to 1.0 mM in an aqueous solution.8. The compound of claim 1 , wherein the compound is an amphipathic molecule capable of forming a complex with the membrane protein for analyzing a structure of the membrane protein using an electron microscope.9. A composition comprising the compound according to for extracting claim 1 , solubilizing claim 1 , stabilizing or crystallizing a membrane protein claim 1 , or analyzing a structure of the membrane protein using an electron ...

Подробнее
23-03-2017 дата публикации

FUNCTIONALISED GRAPHENE

Номер: US20170081195A1
Принадлежит:

Graphene is chemically modified by a process resulting in the introduction of functional groups located only at an edge of the graphene plane. The functionalised graphene finds uses in numerous applications and further chemical synthesis, including a process for coupling an organic or inorganic moiety to the graphene plane via the edge-located functional group. The disclosed products and processes provide highly flexible platforms for the integration of graphene into a variety of applications. 1. Functionalised graphene comprising at least one functional group covalently bonded directly to an edge of a graphene plane , wherein the functional group is only selected from the group consisting of —NO , —NH , —SOH , halide , —N , —MgBr and —SH , and wherein the functional group is only bound to an edge of the graphene plane.2. Functionalised graphene as claimed in claim 1 , wherein the functional group is selected from the group consisting of halide claim 1 , —Nand —MgBr.3. Functionalised graphene as claimed in claim 1 , wherein the functional group is selected from the group consisting of —NO claim 1 , —NH claim 1 , —SOH and —SH.4. Functionalised graphene as claimed in claim 1 , wherein the graphene comprises a plurality of functional groups.5. Functionalised graphene as claimed in claim 4 , wherein the plurality of functional groups are identical.6. A process for the preparation of functionalised graphene as claimed in any preceding claim claim 4 , the process comprising the steps of:a) preparing a sample of graphene to be functionalised,{'sub': 2', '2', '3', '3, 'b) contacting the graphene with one or more reagents suitable for introducing at least one functional group selected from the group consisting of —NO, —NH, —SOH, halide, —N, —MgBr and —SH to any available edge of the sample of graphene, and'}{'sub': 2', '2', '3', '3, 'c) isolating the functionalised graphene bearing only the at least one functional group selected from the group consisting of —NO, —NH, —SOH, ...

Подробнее
12-03-2020 дата публикации

NOVEL GLYCAN CONJUGATES AND METHODS OF USE THEREOF

Номер: US20200078452A1
Автор: Wong Chi-Huey, WU Chung-Yi
Принадлежит:

The present disclosure is directed to vaccines, antibodies, and/or immunogenic conjugate compositions targeting the SSEA3/SSEA4/GloboH associated epitopes (natural and modified) which elicit antibodies and/or binding fragment production useful for modulating the globo-series glycosphingolipid synthesis. The present disclosure relates to methods and compositions which can modulate the globo-series glycosphingolipid synthesis. Particularly, the present disclosure is directed to glycoenzyme inhibitor compound and compositions and methods of use thereof that can modulate the synthesis of globo-series glycosphingolipid SSEA3/SSEA4/GloboH in the biosynthetic pathway; particularly, the glycoenzyme inhibitors target the alpha-4GalT; beta-4GalNAcT-I; or beta-3GalT-V enzymes in the globo-series synthetic pathway. Moreover, the present disclosure is also directed to the method of using the compositions described herein for the treatment or detection of hyperproliferative diseases and/or conditions. 2. The immunogenic composition of claim 1 , wherein L is —OH.3. The immunogenic composition of claim 2 , wherein at least one instance of R claim 2 , R claim 2 , R claim 2 , R claim 2 , Rand Ris —N.4. The immunogenic composition of claim 2 , wherein at least one instance of R claim 2 , R claim 2 , R claim 2 , R claim 2 , Rand Ris —F.7. The immunogenic composition of claim 6 , wherein at least one instance of R claim 6 , R claim 6 , R claim 6 , R claim 6 , R claim 6 , R claim 6 , and Ris —N.8. The immunogenic composition of claim 6 , wherein at least one instance of R claim 6 , R claim 6 , R claim 6 , R claim 6 , R claim 6 , and Ris —F.9. The immunogenic composition of claim 1 , wherein the carrier is a protein claim 1 , a lipid claim 1 , a lipolized protein claim 1 , a virus claim 1 , a peptide claim 1 , or a dendrimer of glycopeptides.10. The immunogenic composition of claim 9 , wherein the carrier is a protein selected from the group consisting of tetanus toxoid (TT) claim 9 , ...

Подробнее
31-03-2022 дата публикации

Compound or salt thereof

Номер: US20220098227A1
Принадлежит: Gunma University NUC, MT3 Inc

There is provided with a compound. The compound is represented by formula or a salt thereof. R 1 is an aliphatic hydrocarbon group having 10 to 26 carbon atoms.

Подробнее
26-03-2015 дата публикации

REACTIVE MULTI-FUNCTIONAL ADDITIVES FOR COATINGS COMPOSITIONS

Номер: US20150087817A1
Принадлежит:

A composition comprising: 1. A composition comprising:(a) from 20 to 60 wt % of a saccharide component comprising from two to five sugar ring units having polymerized units of at least one alkylene oxide selected from the group consisting of ethylene oxide, propylene oxide and butylene oxide bonded to oxygen atoms on said sugar rings and at least three acetoacetyl groups bonded to terminal oxygen atoms of said polymerized units of at least one alkylene oxide; and(b) from 40 to 80 wt % of a non-saccharide component comprising a polyol unit not containing a sugar ring and having a hydroxyl functionality from two to five; said polyol unit having polymerized units of at least one alkylene oxide selected from the group consisting of ethylene oxide, propylene oxide and butylene oxide bonded to hydroxyl oxygen atoms of the polyol and at least two acetoacetyl groups bonded to terminal oxygen atoms of said polymerized units of at least one alkylene oxide;wherein total polymerized units of at least one alkylene oxide comprise from 20 to 80 wt % of said multi-functional additive.2. The composition of wherein the saccharide component comprises two or three sugar ring units and the sugar ring units have a hydroxyl functionality from 4-12.3. The composition of having from 25 to 55 wt % of the saccharide component and from 45 to 75 wt % of the non-saccharide component.4. The composition of wherein total polymerized units of at least one alkylene oxide comprise from 30 to 70 wt % of said multifunctional additive.5. The composition of wherein the saccharide component has formula (S){(CHCH(R)O)R} claim 1 , where S is a sugar ring unit claim 1 , m is an integer from 2 to 5; R is hydrogen claim 1 , methyl claim 1 , ethyl or a mixture thereof; n is from 0.5 to 5 and represents a number average claim 1 , Ris hydrogen or —C(O)CHC(O)CHand k is from 4 to 12 and represents a number average.6. The composition of wherein the non-saccharide component has formula P{(CHCH(R)O)R} claim 5 , where P ...

Подробнее
12-03-2020 дата публикации

GLYCOPOLYMERS SEQUESTERING CARBOHYDRATE-BINDING PROTEINS

Номер: US20200079808A1
Принадлежит:

The invention relates to polymers comprising carbohydrate ligands and moieties, respectively, that bind to carbohydrate-binding proteins (CBPs), as well as to these carbohydrate ligands, and to their use in diagnosis and therapy of diseases that are associated with CBP-mediated cytotoxicity, agglutinatination, or immune complex deposit formation. In particular, the invention relates to polymers comprising a multitude of said carbohydrate ligands and moieties, respectively, mimicking carbohydrates that are bound by CBPs which belong to the group of (i) bacterial exotoxins, (ii) agglutinins, and (iii) immune complex deposit-forming immunoglobulins. Furthermore, the invention relates to the use of these polymers and carbohydrate ligands and moieties respectively, in diagnosis as well as for the treatment of diseases that are associated with CBP-mediated cytotoxicity, agglutinatination, or immune complex deposit formation. In one embodiment, the polymer is polylysine. 4. The polymer of any one of to , wherein said linker Z is —X-A-(B)-(CH)—Y , wherein{'sup': 'a', 'X is N(R);'}{'sup': 'a', 'sub': 1-4', '1-4', '2', '6', '5', '2', '2', '6', '5', '2', '6', '5', '2', '2', '6', '5, 'Ris H, Calkyl, Calkoxy, CHCH, CHCHCH, OCHCH, or OCHCHCH;'}{'sub': 1-7', '1-7', '1-4', '2', '2', 'r', '1-4', '1-7', '1-7, 'sup': b', 'b', 'b, 'A is Calkylene, OCalkylene, Calkylene-(OCHCH)O—C-alkylene, OCalkylene-Ror R—Calkylene wherein Ris an optionally substituted aryl or an optionally substituted heteroaryl, and wherein r is 0 to 6, preferably r is 1, 2 or 3, and further preferably r is 1;'}B is NHC(O) or S;p is 0 or 1;q is 0 to 6, preferably q is 0 to 4, and further preferably q is 0, 2 or 3;{'sub': 3', '2, 'Y is SH, Nor NH.'}5. The polymer of any one of to , wherein said linker Z is —X-A-(B)-(CH)—Y , whereinX is O;{'sub': 1-7', '1-4', '2', '2', 'r', '1-4', '1-7, 'sup': b', 'b, 'A is Calkylene, Calkylene-(OCHCH)OCalkylene or R—Calkylene, wherein Ris an optionally substituted aryl or an ...

Подробнее
21-03-2019 дата публикации

FORMULATION SYSTEMS FOR ANTIMICROBIAL GLYCOLIPIDS

Номер: US20190082689A1
Автор: BITZER Jens, Henkel Thomas
Принадлежит: IMD Natural solutions GmbH

The invention relates to a composition comprising one or more antimicrobial glycolipids and one or more formulation stabilizers. The invention also relates to methods of preparing the compositions and their application in water containing food, beverage, cosmetic, home care and medical products. 2. The composition according to claim 1 , wherein the at least one antimicrobial glycolipid according to general formula (I) is an ester in open chain form claim 1 , wherein the carboxylic acid is a C-C-alkanoic acid.3. The composition according to wherein the formulation component comprises a formulation stabilizer selected from cyclodextrins.4. The composition according to claim 3 , wherein the cyclodextrin is selected from alpha-cyclodextrin claim 3 , beta-cyclodextrin claim 3 , hydroxypropyl-beta-cyclodextrin and methyl-beta-cyclodextrin.557.-. (canceled)58. The composition according to claim 4 , wherein the relative weight ratio of the cyclodextrin to the glycolipid component is 5:1 to 2.5:159. The composition according to claim 1 , wherein the formulation component comprises a formulation stabilizer selected from polysorbates.60. The composition according to claim 59 , wherein the polysorbate is selected from the group consisting of polysorbate 20 claim 59 , polysorbate 21 claim 59 , polysorbate 40 claim 59 , polysorbate 60 claim 59 , polysorbate 61polysorbate 65 claim 59 , polysorbate 80 claim 59 , polysorbate 81 claim 59 , polysorbate 85 claim 59 , polysorbate 120 claim 59 , and a mixture of any of the foregoing.61. The composition according to claim 60 , wherein the relative weight ratio of the polysorbate to the glycolipid component is 20:1 to 8:1.63. The composition according to claim 62 , wherein the rings A and B are xylopyranose moieties and the ring G is a glucopyranose moiety.65. The composition according to claim 64 , wherein at least one of R claim 64 , R claim 64 , R claim 64 , Rand Rmeans —C(═O)C-C-alkyl.67. The composition according to claim 66 , wherein ...

Подробнее
07-04-2016 дата публикации

METHOD OF PURIFYING IDRAPARINUX SODIUM

Номер: US20160096856A1
Принадлежит:

A method for the purification of idraparinux sodium includes: passing a solution including a crude idraparinux sodium through a column including a sodium ion exchange resin to obtain a first mixture; passing a solution including the first mixture through a gel chromatogaphy column to obtain a second mixture; and precipitating a purified idraparinux sodium from a solution including the second mixture. 1. A method for obtaining at least 99.0% pure idraparinux sodium comprising nonasodium methyl 2 ,3 ,4-tri-O-methyl-6-O-sulfonato-α-D-glucopyranosyl-(1→4)-2 ,3-di-O-methyl-β-D-glucopyranuronosyl-(1→4)-2 ,3 ,6-tri-O-sulfonato-α-D-glucopyranosyl-(1-di-O-methyl-α-L-idopyranuronosyl-(1→4)-2 ,3 ,6-tri-O-sulfonato-α-D-glucopyranoside , the method comprising:passing a solution comprising a crude idraparinux sodium through a column comprising a sodium ion exchange resin to obtain a first mixture;passing a solution comprising the first mixture through a gel chromatography column to obtain a second mixture; andprecipitating a purified idraparinux sodium from a solution comprising the second mixture.2. The method of claim 1 , wherein the precipitating of the purified idraparinux sodium from the solution comprising the second mixture is performed utilizing a first solvent.3. The method of claim 1 , wherein the passing of the solution comprising the crude idraparinux sodium through the column comprising the sodium ion exchange resin comprises:dissolving the crude idraparinux sodium in a second solvent to obtain the solution comprising the crude idraparinux sodium,passing the solution comprising the crude idraparinux sodium through the column comprising the sodium ion exchange resin, andcollecting and concentrating an eluent of the column comprising the sodium ion exchange resin to obtain the first mixture.4. The method of claim 3 , wherein the second solvent comprises water.5. The method of claim 3 , wherein a concentration of the crude idraparinux sodium in the second solvent is ...

Подробнее
26-06-2014 дата публикации

LONG CHAIN GLYCOLIPIDS USEFUL TO AVOID PERISHING OR MICROBIAL CONTAMINATION OF MATERIALS

Номер: US20140178444A1
Принадлежит: IMD Natural solutions GmbH

The invention relates to the use of, and methods of use employing, certain glycolipid compounds as defined in detail below and having preservative or antimicrobial properties, novel compounds of the glycolipid class, and related invention embodiments. 2. Method according to claim 1 , where the material to which the compound is added is a cosmetic claim 1 , a food or a beverage.5. Method according to claim 1 , where at least one additional preservative is added.6. Method according to claim 1 , where the compound or compounds of the formula I claim 1 , a physiologically acceptable salt thereof claim 1 , and/or an ester thereof claim 1 , is added in the form of an extract from a natural source or obtained from such an extract.7Dacryopinax spathulariaDitiola radicataDitiola nudaFemsjonia luteoalbaDitiola pezizaeformis. Method according to claim 6 , where the source of the extract is strain FU50088 claim 6 , strain MUCL 53180 claim 6 , strain CBS 173.60 or -(=) strain MUCL 53500.10. A preservative or antimicrobial composition claim 8 , comprising as active agent a compound or a mixture of compounds of the formula I claim 8 , a physiologically acceptable salt thereof claim 8 , and/or an ester thereof claim 8 , as shown or defined in claim 8 , alone or with another additive claim 8 , optionally a carrier material.11. The composition according to claim 10 , which is a precursor of a beverage.12. An extract comprising one or more compounds of the formula I claim 8 , a physiologically acceptable salt thereof claim 8 , and/or an ester thereof claim 8 , as shown or defined in .13. A method of enhancing microbial stability of a material claim 8 , comprising adding one or more compounds of the formula I claim 8 , a physiologically acceptable salt thereof claim 8 , and/or an ester thereof claim 8 , as shown or defined in to a material claim 8 , selected from the group consisting of a cosmetic claim 8 , a food claim 8 , a beverage claim 8 , a pharmaceutical claim 8 , a medical ...

Подробнее
14-04-2016 дата публикации

Beta-mannosylceramide and stimulation of nkt cell anti-tumor immunity

Номер: US20160101123A1

β-mannosylceramides or salts or solvates thereof in a pharmaceutically acceptable carrier, for use as a Type I NKT cell agonist in conjunction with a therapeutically effective amount of α-galactosylceramide or a salt or a solvate thereof, and/or at least one or more T-cell co-stimulatory molecules, disclosed. Compositions comprising β-mannosylceramide, as well as methods of treatment of tumors are also provided.

Подробнее
26-06-2014 дата публикации

Novel compound isolated from quamoclit, and composition for preventing or treating diabetes containing the compound as an active ingredient

Номер: US20140179622A1

The present invention relates to a novel compound isolated from Quamoclit sp., and more particularly to a novel compound isolated from Quamoclit sp. and a composition for preventing or treating diabetes and its complications comprising the compound as an active ingredient. The novel compound isolated from Quamoclit sp. according to the present invention has excellent effects on lowering blood sugar, promoting insulin secretion, inhibiting VEGF expression, and so on. Thus, the present invention not only functions to prevent or treat diabetes and its complications, but also functions to promote treatment effects when treated together with conventional diabetes medicines.

Подробнее
26-06-2014 дата публикации

Acadesine derivatives, products and compositions including same, therapuetic uses thereof, and methods for synthesizing same

Номер: US20140179626A1

Acadesine derivatives as a drug, as well as the derivatives for the treatment of cancer and in particular for the treatment of chronic myeloid leukemia are described. Also, product containing the derivatives and at least one second active ingredient as a combination product for simultaneous, separate or sequential administration, in the treatment of cancer, as well as a pharmaceutical composition containing the derivatives and a pharmaceutically acceptable carrier are described. Finally, a method for inhibiting the in vitro cell proliferation including the placement of an in vitro cell in contact with the derivatives and methods for synthesis of said derivatives and methods for synthesis of the derivatives are described.

Подробнее
13-04-2017 дата публикации

C-glycoside derivative

Номер: US20170101388A1
Автор: Frank Wu
Принадлежит: Xuanzhu Pharma Co Ltd

The present invention involves a compound represented by general formula (I), a derivative thereof and a use thereof: wherein R 1 , R 2 , R 3 , R 4 , R 5a , R 5b , R 5c and X are defined as in the description.

Подробнее
08-04-2021 дата публикации

Organotellurium Compounds, Compositions and Methods of Use Thereof

Номер: US20210102949A1
Принадлежит:

A compound of formula (I): 139.-. (canceled)40. A kit comprising a telloruphene mass tag comprising a distinct tellurium isotope and instructions or reagents for reconstituting , mass tagging and/or using the compound or composition in a mass detection assay.41. The kit of claim 40 , wherein the tellurophene mass tag comprises more than one atom of the distinct tellurium isotope.42. The kit of claim 40 , wherein the tellurophene mass tag is conjugated to a biologically active material claim 40 , wherein the biologically active material is selected from affinity reagent claim 40 , polypeptide claim 40 , nucleic acid claim 40 , peptidic nucleic acid claim 40 , oligosaccharide claim 40 , polysaccharide lipopolysaccharide claim 40 , hormone claim 40 , pharmacologically active substance claim 40 , steroid claim 40 , vitamin claim 40 , amino acid and sugar.4352.-. (canceled)53. A method of detecting or quantifying a target analyte by mass cytometry comprising the steps of:a. providing a cell or cell population;b. providing a tellurophene mass tagged biologically active material, wherein the biologically active material specifically binds or reacts with the target analyte;c. mixing the cell or cell population with the tellurophene mass tagged biologically active material; andd. detecting tellurium labeling and/or quantitating the amount of tellurium labeling of the cell or cell population by mass cytometry;wherein the biologically active material comprises a distinct tellurium isotope;wherein the biologically active material is selected from affinity reagent, polypeptide, nucleic acid, peptidic nucleic acid, oligosaccharide, polysaccharide lipopolysaccharide, hormone, pharmacologically active substance, steroid, vitamin, amino acid and sugar, optionally the affinity reagent is selected from a polypeptide affinity reagent, aptamer, nucleic acid or lectin.54. The method of claim 53 , wherein the mass cytometry comprises analysis of a single cell.55. The method of claim 53 , ...

Подробнее
04-04-2019 дата публикации

Anthracycline Derivatives For Treating Tumor Diseases

Номер: US20190100548A1
Принадлежит: PRODUKEM MOLEKULARES DESIGN GmbH

The invention relates to anthracycline derivative compounds for treating tumor diseases, and related methods, compositions, and kits.

Подробнее